Single chain polypeptides activated on use

By designing specific enzyme cleavage sites in single-stranded polypeptides, they are activated only in specific parts of the human body, solving the problems of safety and production safety in the prior art, achieving safe and convenient use and efficient production, suitable for treatment Muscle spasms, dynamic wrinkles and body shape.

CN119060198APending Publication Date: 2024-12-03YSTE (HAINAN) AESTHETIC MEDICINE HEALTH TECH CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410701677.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-05-31
Filing Date
2024-05-31
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The prior art cannot safely and effectively produce and use single-stranded polypeptides for the treatment of muscle spasms, dynamic wrinkles and body contour shaping, and there are safety and production safety issues in activated forms.

Method used

A single-chain polypeptide that is activated and attenuated at a specific site of use is designed, which comprises a first domain, an intermediate amino acid sequence region and a second domain, which contains an enzyme cleavage site and is only in a specific site of the human body. The protease is highly specific and converted into an activated form after cleavage, ensuring safe and convenient use and production.

Benefits of technology

Improve the safety and practicality of the product, and through the design of specific cleavage sites, avoid accidental ingestion or non-specific activation, ensure the safety of production and use, and reduce the risk of intracellular expression through in vitro synthesis methods. Short cycle and low cost.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119060198A_ABST
    Figure CN119060198A_ABST
Patent Text Reader

Abstract

The invention provides a single-chain polypeptide which is highly activated and attenuated after entering a specific use site and can be produced more safely and conveniently, corresponding application of the single-chain polypeptide, nucleic acid encoding the single-chain polypeptide and a preparation method of the single-chain polypeptide, and the single-chain polypeptide comprises a first structural domain, an intermediate amino acid sequence region and a second structural domain, the intermediate amino acid sequence region is located between the first structural domain and the second structural domain, the sequence of the intermediate amino acid sequence region contains at least one first enzyme cutting site, and the first enzyme cutting site is designed to be capable of being highly specifically cut by first protease existing in a specific part of a human body; the single-chain polypeptide is converted into an activated form capable of inhibiting release of information substances after being cut by the first protease at the first enzyme cutting site.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biotechnology, and specifically relates to a single-chain polypeptide activated during use, and specifically relates to a single-chain polypeptide, and its corresponding application, a nucleic acid encoding the single-chain polypeptide, and a preparation method thereof. Background Art

[0002] Currently, some toxin molecules with specific cleavage components can achieve applications such as the following:

[0003] (1) Therapeutic applications: treatment of hemifacial spasm, essential blepharospasm, spasmodic torticollis, spastic cerebral palsy, post-stroke limb spasm, tremor and other types of dystonia;

[0004] (2) Application in minimally invasive plastic surgery:

[0005] Including wrinkle removal of various dynamic wrinkles such as frown lines, forehead lines, crow's feet, etc.; beautification of facial contours such as eyebrow height adjustment, mental muscle relaxation, mandibular margin lifting, neck line injection, etc.

[0006] Reshaping of body contours such as reducing the masseter muscle, reducing the gastrocnemius muscle, reducing the trapezius muscle, etc.

[0007] However, there is currently no product that can be safely and effectively produced and used to achieve the aforementioned effects. Summary of the invention

[0008] The present invention provides a single-chain polypeptide which is highly activated and attenuated after entering a specific use site and can be produced more safely and conveniently, and its corresponding application, nucleic acid encoding the single-chain polypeptide, and its preparation method.

[0009] To this end, the present invention provides the following technical solutions:

[0010] The present invention provides a single-chain polypeptide, characterized in that it includes: a first domain, an intermediate amino acid sequence region, and a second domain, wherein the intermediate amino acid sequence region is between the first domain and the second domain, and the intermediate amino acid sequence region sequence contains at least one first enzyme cleavage site, and the first enzyme cleavage site is designed to be highly specifically cleaved by a first protease existing in a specific part of the human body, and the single-chain polypeptide is converted into an activated form that can inhibit the release of information substance after being cleaved by the first protease at the first enzyme cleavage site.

[0011] The single-chain polypeptide provided by the present invention also has the following characteristics: wherein the first domain has a molecular weight of about 50 kDa, the second domain has a molecular weight of about 100 kD, and the first domain has cleavage activity.

[0012] The single-chain polypeptide provided by the present invention also has the following characteristics: wherein the information substance is an intercellular information substance, preferably any one of a neurotransmitter, an endocrine hormone, a local chemical mediator and a gas signal molecule, and more preferably the information substance is acetylcholine.

[0013] The single-chain polypeptide provided by the present invention also has the following characteristics: wherein the first domain is a non-toxic cell protease or a fragment thereof that can cut the protein of the exocytosis fusion apparatus of the target cell; the second domain has a binding portion and a transport portion, the binding portion can bind to the target cell receptor and enter the endosome of the target cell through receptor-mediated endocytosis, and the transport portion can transport the first domain into the cytosol of the target cell;

[0014] Preferably, the first enzyme cleavage site is between the first domain and the transport portion, and / or the binding portion is carboxyl-terminal and has a molecular weight of about 50 kD, and the transport portion is amino-terminal and has a molecular weight of about 50 kD;

[0015] Another preferred embodiment is that the protein of the exocytosis fusion apparatus is the neuronal snare protein, and / or the target binding site is a receptor on the presynaptic membrane of the neuron.

[0016] The single-chain polypeptide provided by the present invention also has the following characteristics: wherein the first domain at least includes a part of the L chain of the Clostridium neurotoxin:

[0017] Preferably, the portion of the Clostridium neurotoxin L chain is the neurotoxin L chain of one of Clostridium botulinum subtypes A, B, C, D and E or is derived therefrom, and / or the first domain contains an amino acid sequence that is at least 35%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 99% or 100% identical to SEQ ID NO: 10, or contains an amino acid sequence that is at least 35%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 99% or 100% identical to any one of 11-16 except for the naturally occurring enzyme cleavage sequence; and / or

[0018] The second domain comprises at least a portion of a Clostridium neurotoxin H chain, preferably a portion of the Clostridium neurotoxin H chain is a neurotoxin heavy chain of one of the following: Clostridium botulinum subtype A, Clostridium botulinum subtype B, Clostridium botulinum subtype C, Clostridium botulinum subtype D, Clostridium botulinum subtype E, Clostridium botulinum subtype F, Clostridium botulinum subtype G, Clostridium baratii and Clostridium butyricum; or a portion of the Clostridium neurotoxin H chain is a neurotoxin H chain of Clostridium tetani or is derived therefrom, and / or

[0019] The second domain comprises an amino acid sequence that is at least 35%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 99% or 100% identical to any one of SEQ ID NOs: 17-23.

[0020] The single-chain polypeptide provided by the present invention also has the following characteristics: wherein the number of amino acids in the linker (L1) between the first domain and the intermediate amino acid sequence region is 0-20 or 0-10 amino acids or 0-5; and / or the number of amino acids in the linker (L2) between the intermediate amino acid sequence region and the second domain is 0-20 or 0-10 amino acids or 0-5.

[0021] The single-chain polypeptide provided by the present invention also has the following characteristics: wherein the first protease is not a protease existing in the human digestive tract,

[0022] Preferably, the specific part of the human body is human skin tissue, and / or at least one of the first proteases is selected from the following:

[0023] Any one or more of epidermal specific kallikrein (KLKs) proteases (e.g., KLK5, KLK6, KLK7), SASPase proteases, Caspase proteases (e.g., Caspase-14), Furin proteases, and their respective variants retaining enzymatic activity; and / or,

[0024] The first enzyme cleavage site contains an amino acid sequence that is at least 50%, 60%, 85%, 90%, 99% or 100% identical to any one of SEQ ID NOs: 1-4, SEQ ID NO: 50 and SEQ ID NO: 51.

[0025] In SEQ ID NO:50 and SEQ ID NO:51, "X" in RXXR and RRXX is any amino acid, preferably, XX in RXXR is RK, TK or TR; "XX" in RRXX is SV or KR.

[0026] The single-chain polypeptide provided by the present invention also has such a feature, and further comprises: any one or more of a signal peptide for increasing the expression amount, a quantitative protein for quantification, and a tag protein, and further, one or more of the signal peptide, the quantitative protein, and the tag protein are respectively defined as follows: the signal peptide contains an amino acid sequence that is at least 80%, 85%, 90%, 99% or 100% identical to SEQ ID NO: 24; the quantitative protein is a fluorescent protein;

[0027] The tag protein is one or more of a His tag, a GST tag, an MBP tag and a Strep-tagII tag.

[0028] The single-chain polypeptide provided by the present invention also has the following characteristics, and further comprises: two second enzyme cleavage sites respectively located at the N-terminus of the first domain and the C-terminus of the second domain, and the second protease that cleaves the second enzyme cleavage site cannot cleave the first enzyme cleavage site.

[0029] The single-chain polypeptide provided by the present invention also has the following characteristics: wherein, the first enzyme cleavage site and / or the second enzyme cleavage site are usually not cleaved by the protease contacted during the expression of the single-chain polypeptide in the host cell in vivo or the synthesis of the single-chain polypeptide by an in vitro synthesis system involving cell extracts from host cells.

[0030] The single-chain polypeptide provided by the present invention also has the following characteristics: wherein the second enzyme cleavage site is designed to be highly specific to the second protease, preferably, the second protease is selected from non-human enterokinase, tobacco etch virus protease, protease derived from Bacillus subtilus, protease derived from Bacillus amyliquifaciens, protease derived from rhinovirus, papain, homologues of insect papain or homologues of crustacean papain; and / or

[0031] The second enzyme cleavage site contains an amino acid sequence that is at least 85%, 90%, 99% or 100% identical to any one of SEQ ID NOs: 5-9.

[0032] The single-chain polypeptide provided by the present invention also has the following characteristics: wherein the intermediate amino acid sequence region sequence further includes XTXS, wherein X is not a K amino acid, preferably: X is a Q amino acid; and / or

[0033] The structure of the intermediate amino acid sequence region sequence from N-terminus to C-terminus is:

[0034] XTXS-linker (L3) - at least one first enzyme cleavage site, further, the number of amino acids in L3 is 0-20 or 0-10 or 0-5, and further, the number of the first enzyme cleavage site is 1.

[0035] The single-chain polypeptide provided by the present invention also has the following characteristics: when the second domain contains an amino acid sequence that is at least 80%, 85%, 90%, 95%, 99% or 100% identical to SEQ ID NO: 17, the lysine at the position corresponding to the 423rd position of the amino acid sequence of the second domain is mutated to a non-lysine.

[0036] The single-chain polypeptide provided by the present invention also has the following characteristics: wherein the first domain, the middle amino acid sequence region and the second domain are connected from the N-terminus to the C-terminus; and / or when there are multiple first enzyme cleavage sites, multiple first enzyme cleavage sites are sequentially connected from the N-terminus to the C-terminus, all the first enzyme cleavage sites have the same cleavage site or each first enzyme cleavage site is different, and the number of amino acids in the linker (L4) between the multiple cleavage sites is 0-20 or 0-10 amino acids or 0-5.

[0037] The present invention also provides an application of the single-chain polypeptide as described above: the application includes any one or more of the following: skin care, plastic surgery, body shaping, and treatment by inducing muscle relaxation and relieving muscle spasms.

[0038] The present invention also provides a use of the single-chain polypeptide as described above in the preparation of products or medicines for specific purposes: the specific purposes include any one or more of the following: skin care, plastic surgery, body shaping, and treatment by inducing muscle relaxation and relieving muscle spasms.

[0039] The present invention also provides a single-chain polypeptide product or medicine, characterized in that it comprises: the single-chain polypeptide as described above, preferably, the product or medicine has applications including any one or more of the following: skin care, plastic surgery, body shaping, and treatment by inducing muscle relaxation and relieving muscle spasms;

[0040] Another preferred embodiment is that the product or drug is applied to a specific part of the human body by smearing, spraying, external application or injection.

[0041] The present invention also provides a nucleic acid, characterized in that it comprises: a nucleotide sequence encoding the single-chain polypeptide as described above.

[0042] The present invention also provides a vector, characterized in that it comprises: the nucleic acid as described above.

[0043] The present invention also provides a host cell, characterized in that the aforementioned nucleic acid is integrated and / or the aforementioned vector is included.

[0044] The host cell provided by the present invention also has the following characteristics: the host cell is derived from a prokaryotic cell or a eukaryotic cell, and further, the cell is selected from the following group: a combination of one or more of Escherichia coli cells, human cells, Chinese hamsters, ovarian cells, insect cells, wheat germ cells, rabbit reticulocytes and yeast cells.

[0045] The host cell provided by the present invention also has the following characteristics: wherein the host cell is selected from yeast cells, and further, the yeast cell is selected from: a combination of one or more of Saccharomyces cerevisiae and Kluyveromyces yeast. In another preferred embodiment, the Kluyveromyces yeast is selected from: a combination of one or more of Kluyveromyces lactis, Kluyveromyces marxianus and Kluyveromyces dobsonii.

[0046] The present invention also provides an in vitro cell-free synthesis system, characterized in that the single-chain polypeptide is synthesized using mRNA or DNA encoding the single-chain polypeptide as a template.

[0047] The in vitro cell-free synthesis system provided by the present invention also has the following characteristics, including any one or more of the following:

[0048] (1) mRNA or DNA template encoding the single-chain polypeptide;

[0049] (2) a cell extract, wherein the cell extract is a yeast cell extract, and further, the cell extract is derived from the following strains: any one or more combinations of Saccharomyces cerevisiae, Pichia pastoris and Kluyveromyces; preferably, the yeast cell extract is derived from Kluyveromyces, more preferably Kluyveromyces lactis;

[0050] (3) Any one or more of the following components:

[0051] Amino acid mixture, dNTP, RNA polymerase, DNA polymerase, energy supply system, polyethylene glycol and aqueous solvent.

[0052] The present invention also provides a method for preparing the aforementioned single-chain polypeptide, characterized in that:

[0053] The single-chain polypeptide is obtained by performing an in vitro synthesis reaction using mRNA or DNA encoding the single-chain polypeptide as a template,

[0054] Preferably, the in vitro synthesis reaction is carried out in a reaction system comprising the aforementioned in vitro cell-free synthesis system.

[0055] Furthermore, the volume ratio of the DNA template to other components involved in the in vitro synthesis reaction ranges from 1:10 to 1:50 or 1:20 to 1:40 or 1:25 to 1:35 or 1:30.

[0056] The preparation method provided by the present invention also has the following characteristics: wherein the cell-free in vitro synthesis system comprises: yeast cell extract, amino acid mixture, dNTP, RNA polymerase, DNA polymerase, energy supply system, polyethylene glycol and aqueous solvent;

[0057] Further:

[0058] The yeast cell extract is from the following group of strains: any one or more combinations of Saccharomyces cerevisiae, Pichia pastoris and Kluyveromyces; preferably, the yeast cell extract is from Kluyveromyces, more preferably Kluyveromyces lactis.

[0059] The preparation method provided by the present invention also has the following characteristics: wherein the yeast cell extract accounts for 50-80% of the volume of the entire cell-free in vitro protein synthesis system.

[0060] The preparation method provided by the present invention also has the following characteristics: it also includes: using a second protease to enzymatically digest the obtained single-chain polypeptide including the second enzyme cleavage site to obtain a single-chain polypeptide including only the first domain, the middle amino acid sequence region and the second domain.

[0061] The present invention also provides a use of the aforementioned nucleic acid or the aforementioned vector or the aforementioned host cell or the aforementioned in vitro cell-free synthesis system in the preparation of the aforementioned single-chain polypeptide.

[0062] Function and Effect of the Invention

[0063] The present invention provides a single-chain polypeptide that is activated when used, specifically a single-chain polypeptide, and its corresponding application, a nucleic acid encoding the same, and a preparation method thereof, which has at least the following advantages:

[0064] (1) The first enzyme cleavage site between the first domain and the second domain of the single-chain polypeptide provided by the present invention is designed to be highly specifically cleaved by a first protease present in a specific part of the human body. In this way, when the single-chain polypeptide is used in a specific part, the first enzyme cleavage site enters the specific use part and is then highly specifically cleaved by the first protease present in the specific part of the human body and converted into an activated form. Compared with the current method of being activated before leaving the factory, the safety of use is greatly improved. In particular, when used on skin tissue, due to its safety, it can be used safely and conveniently by applying and the like, thereby improving the usability, practicality and universality of the product.

[0065] (2) Furthermore, since the first protease does not exist in the human digestive tract, it will not be activated even if accidentally ingested, further improving the safety of use;

[0066] (3) Moreover, since the first enzyme cleavage site of the single-chain polypeptide is designed to be highly specifically cleaved by the first protease present in the specific part of the human body, and then the single-chain polypeptide is highly converted into an activated form, the production is safer, which not only ensures the safety of upstream production, but also ensures the safety of downstream product production. In particular, when the single-chain polypeptide of the present invention is synthesized in vitro using the mRNA or DNA encoding the single-chain polypeptide of the present invention as a template, some risks caused by leakage of the strain used in the intracellular expression synthesis method will not occur, and the cycle is short, the method is simple, and the cost is low, which further improves safety and practicality. BRIEF DESCRIPTION OF THE DRAWINGS

[0067] Figure 1 The middle is the electrophoresis diagram of the modified protein obtained after elution and purification under pH 8.0 conditions in the embodiment;

[0068] Figure 2 A reference chart for scoring the effects in animal experiments;

[0069] Figure 3 This is a diagram of the animal experiment results of Example 7;

[0070] Figure 4 and Figure 5 The substrate conversion rates of different concentrations of substrate CFP-SNAP25(17aa)-YFP and substrate CFP-SNAP25(66aa)-YFP are shown in Example 6;

[0071] Figure 6 This is a result diagram comparing the activity effects of TEV single-enzyme cleavage products and double-enzyme cleavage products in Example 6 to exclude the influence of TEV enzyme;

[0072] Figure 7 This is a result diagram for comparing the activity effects of the double enzyme digestion product and the KLK5 enzyme in implementation 6 to exclude the influence of the KLK5 enzyme;

[0073] Figure 8 In Example 6, the in vitro activity detection of single enzyme cleavage at multiple first enzyme cleavage sites;

[0074] Fig. 9 It is the test result figure of LD50 in Example 8;

[0075] Fig.10 This is a graph showing the ED50 detection results in Example 9. DETAILED DESCRIPTION

[0076] The specific implementation of the present invention is described below in conjunction with the accompanying drawings. For the specific methods or materials used in the embodiments, those skilled in the art can make conventional replacement selections based on the technical ideas of the present invention and according to existing technologies, and are not limited to the specific description of the embodiments of the present invention.

[0077] Unless otherwise specified, the methods used in the examples are all conventional methods; the materials, reagents, etc. used, unless otherwise specified, can be obtained from commercial sources.

[0078] 1. Description of single-chain polypeptide

[0079] Signal transduction refers to the process of transmitting extracellular information into cells. It is the basic concept of cell communication, emphasizing the generation, secretion and transmission of signals, that is, the information substance is released from the synthesized cell and then transmitted. After the receptor recognizes the corresponding ligand (first messenger) and binds to it, intracellular cyclic adenosine monophosphate (cAMP), cyclic guanosine monophosphate (cGMP), calcium ions, inositol phospholipids (second messengers) and other substances increase, participate in various biological regulation processes of the cell, enhance, differentiate, integrate and transmit the obtained information to the effector, so as to exert specific physiological functions or pharmacological effects.

[0080] Information transduction between human cells can be achieved through direct contact between adjacent cells, but more importantly and more commonly, it is through the secretion of various chemical substances by cells to regulate their own and other cells' metabolism and function. Therefore, in the human body, information transduction pathways are usually composed of specific cells that secrete and release information substances, information substances (including intercellular and intracellular information substances and carriers, transport pathways, etc.) and target cells (including specific receptors, etc.).

[0081] Information substances can be divided into intercellular information substances and intracellular information molecules.

[0082] All chemical substances secreted by cells that regulate the life activities of target cells are collectively called intercellular information substances, that is, first messengers. According to the way cells secrete information substances, intercellular information substances can be divided into neurotransmitters, endocrine hormones, local chemical mediators and gas signal molecules. Chemical substances that transmit cell regulation signals within cells are called intracellular information substances, and their composition is diverse. Usually Ca 2+ Small molecules that transmit information within cells, such as cAMP, cGMP, DAG, IP3, Cer, arachidonic acid and its metabolites, are called second messengers. Substances responsible for transmitting information inside and outside the cell nucleus are called third messengers, which can bind to specific sequences of target genes and play the role of transcription factors or transcription regulators.

[0083] Neurotransmitters are information substances that transmit information between neurons or between neurons and effector cells such as muscle cells, glandular cells, etc. According to the chemical composition characteristics of neurotransmitters, there are mainly choline (acetylcholine, English name, acetylcholine, referred to as Ach), monoamines (norepinephrine, dopamine and 5-hydroxytryptamine), amino acids (excitatory neurotransmitters such as glutamate and aspartic acid; inhibitory neurotransmitters such as γ-aminobutyric acid, glycine and taurine) and neuropeptides.

[0084] The synthesis of acetylcholine (Ach) is mainly carried out in cholinergic nerve endings. When the nerve impulse reaches the nerve endings, the vesicle membrane fuses with the presynaptic membrane to release acetylcholine into the synaptic cleft, stimulating the corresponding receptors on the postsynaptic membrane, causing a series of physiological effects. At the same time, acetylcholine is hydrolyzed into choline and acetic acid by cholinesterase (ChE) at the nerve endings and inactivated. Part of the choline is taken up by the cholinergic nerve endings again and participates in the synthesis of new acetylcholine.

[0085] Existing studies have shown that by inhibiting the transmission of acetylcholine, it can lead to muscle relaxation, relieve muscle spasms, regulate hypertonia and movement disorders as well as dynamic wrinkles; in addition, it can also reduce muscle volume by causing muscle disuse atrophy to achieve body shaping.

[0086] Non-cytotoxic proteases act by proteolytically cleaving intracellular transporters called SNARE proteins (see Gerald K (2002) - Cell and Molecular Biology (4th edition) John Wiley & Sons, Inc.).

[0087] The acronym SNARE is derived from the term Soluble NSF Attachment Receptor, where NSF stands for N-ethylmaleimide-Sensitive Factor.

[0088] SNARE protein is necessary for intracellular vesicle fusion, and therefore is necessary for secretion of molecules from cells via vesicle transport. Non-cytotoxic protease function is zinc-dependent endopeptidase activity and shows high substrate specificity for SNARE protein. SNARE protein is associated with the membrane or cell membrane of secretory vesicles, and promotes the exocytosis of molecules by mediating the fusion of secretory vesicles with cell membranes, thereby allowing the contents of the vesicles to be discharged from the cell. Cutting of neuronal SNAREs prevents the release of neurotransmitters, thereby causing paralysis. Therefore, once non-cytotoxic proteases are delivered to desired target cells, non-cytotoxic proteases can inhibit cell secretion by desired target cells.

[0089] The three proteins at the synaptic terminals, synaptobrevin VAMP on the synaptic vesicle membrane, syntaxin and SNAP-25 on the presynaptic membrane are all called SNARE proteins.

[0090] The single-chain polypeptide provided by the present invention comprises: a first structural domain, an intermediate amino acid sequence region, and a second structural domain.

[0091] The middle amino acid sequence region and the first domain may be separated by amino acids (linker, L1>0) or directly connected (L1=0). Similarly, the first cleavage site and the second domain may be separated by amino acids (linker, L2>0) or directly connected (L2=0).

[0092] In one example, the number of amino acids in the linker (L1) between the first domain and the middle amino acid sequence region is 0-20 or 0-10 amino acids or 0-5.

[0093] In one example, the number of amino acids in the linker (L2) between the middle amino acid sequence region and the second domain is 0-20 or 0-10 amino acids or 0-5.

[0094] The intermediate amino acid sequence region sequence contains at least one first enzyme cleavage site, and when there are multiple first enzyme cleavage sites:

[0095] These first enzyme cleavage sites may be identical, all identical, or different from each other;

[0096] A plurality of the first enzyme cleavage sites are sequentially connected from the N-terminus to the C-terminus;

[0097] The number of amino acids in the linker (L4) between the plurality of restriction sites is 0-20 or 0-10 amino acids or 0-5.

[0098] The first enzyme cleavage site is designed to be highly specifically cleaved by a first protease in a specific part of the human body. The single-chain polypeptide is converted into an activated form after being cleaved by the first protease at the first enzyme cleavage site. The activated form of the single-chain polypeptide can inhibit the release of the aforementioned information substance.

[0099] The specific part of the human body is the part where the single-chain polypeptide enters the human body when used by the human body, such as the digestive tract, skin tissue, cells, etc. When used, there are many ways to enter the specific part of the human body, for example, for skin tissue, it can be smearing, external application, spraying, injection, etc.

[0100] The highly specific cleavage in this article means that under normal circumstances, the enzyme cleavage site is mainly recognized and cleaved by the corresponding specific protease and cannot be cleaved by other proteases, that is, under most conditions, the enzyme cleavage site and the corresponding protease have a unique correspondence.

[0101] Specifically, "the first enzyme cleavage site is designed to be highly specifically cleaved by the first protease present in the specific part of the human body where the single-chain polypeptide is used" means that the first enzyme cleavage site, under most conditions, has a unique correspondence with one or several first proteases present in the specific part of the human body. For example, when the use site is the digestive tract, it has a unique correspondence with one or several proteases present in the digestive tract. For another example, when the use site is skin tissue, it has a unique correspondence with one or several proteases present in the skin tissue.

[0102] In this way, the single-chain polypeptide is only used in a specific part of the human body where the aforementioned first protease exists, for example, applied to the skin surface and enters the skin tissue. The first enzyme cleavage site is cleaved by the first protease that is highly specific to the first enzyme cleavage site in the skin tissue, thereby converting the single-chain polypeptide into an activated form that can inhibit the release of information substance.

[0103] The activated form of the single-chain polypeptide is a double-chain structure in which the first domain and the second domain are connected by a disulfide bond. In the activated form, the disulfide bond is reduced, thereby generating a product with cleavage activity, so that the release of information substances such as neurotransmitters can be inhibited. The cleavage activity referred to herein is, for example, cleavage of proteins associated with vesicles and / or plasma membranes involved in cell exocytosis:

[0104] In essence, the first domain and the second domain are separated by the intermediate amino acid sequence region, and the intermediate amino acid sequence region contains the first enzyme cleavage site, but does not contain a non-wild-existing enzyme cleavage amino acid sequence, that is, a non-naturally existing enzyme cleavage amino acid sequence between the first domain and the second domain (a wild-existing enzyme cleavage amino acid sequence or a naturally existing enzyme cleavage amino acid sequence refers to a naturally existing single-chain polypeptide, which can be transformed from a single-chain to a double-chain active structure by enzyme cleavage of this naturally existing enzyme cleavage amino acid sequence), which is equivalent to replacing the wild-existing enzyme cleavage amino acid sequence with the first enzyme cleavage site, so that it can be cleaved only under the highly specific action of the first protease. For example, when the first domain is the light chain of botulinum toxin type A and the second domain is the light chain of botulinum toxin type A, the intermediate amino acid sequence region does not contain the "KTKSLDKGYNK" sequence that is naturally cleaved by enzymes (natural enzyme cleavage site sequence).

[0105] In one example, the information substance is acetylcholine.

[0106] Experiments have confirmed that the activated form of the single-chain polypeptide, that is, the aforementioned double-chain structure, can play a role in relaxing muscles, that is, it has the function of inhibiting the transmission of information substances such as neurotransmitters.

[0107] Preferably, the first domain, the first enzyme cleavage site and the respective parts of the second domain are connected from the N-terminus to the C-terminus.

[0108] In one example, the first domain has a molecular weight of about 50 kDa,

[0109] The second domain has a molecular weight of approximately 100 kD.

[0110] In a specific example, the single-chain polypeptide designed by the present invention, the first domain is a non-toxic cellular protease or a fragment thereof that can cut the protein of the exocytosis fusion apparatus of the target cell. In one example, the cell is a neuronal cell, the protein of the exocytosis fusion apparatus is the neuronal snare protein, and / or the target binding site is a receptor on the presynaptic membrane of the neuron.

[0111] When the protein of the exocytotic fusion apparatus is the SNARE protein of a neuronal cell, the physiological function of cholinergic nerve conduction is blocked by cutting the SNARE protein, for example, preventing the release of the acetylcholine neurotransmitter.

[0112] In one example, the SNARE protein is selected from the group consisting of: VAMP, syntaxin, and SNAP-25.

[0113] The second domain has a binding portion and a transport portion:

[0114] The binding moiety can bind to a target cell receptor and be taken up in the endosome of the target cell by receptor-mediated endocytosis, for example, binding to presynaptic extrasynaptic receptors (ectoacceptors) on nerve terminals.

[0115] Transport The transport moiety is capable of transporting the first domain into the cytosol of a target cell.

[0116] The binding part of the second domain binds to the target cell receptor and is received in the endosome of the target cell through receptor-mediated endocytosis. The transport part brings the first domain into the cytosol of the target cell. In the cytosol, the second domain is cut off by reducing the disulfide bond, and the first domain is released into the cytosol, thereby cutting the SNARE protein and inhibiting the release of neurotransmitters, thereby causing muscle relaxation and relieving muscle spasms, thereby regulating hypertonia, movement disorders and dynamic wrinkles; and achieving muscle disuse atrophy and reducing muscle volume for body shaping.

[0117] The binding portion is the carboxyl terminal with a molecular weight of approximately 50 kD, and the transport portion is the amino terminal with a molecular weight of approximately 50 kD.

[0118] In one example, the first domain comprises at least a portion of a Clostridium neurotoxin L chain, preferably the portion of the Clostridium neurotoxin L chain is a neurotoxin L chain of one of Clostridium botulinum subtypes A, B, C, D and E or is derived therefrom; and / or,

[0119] The first domain comprises an amino acid sequence having at least 35%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 99% or 100% identity to SEQ ID NO: 10, or an amino acid sequence having at least 35%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 99% or 100% identity to any one of 11-16, with the naturally occurring restriction enzyme sequence removed;

[0120] In one example, the second domain includes at least a portion of the Clostridium neurotoxin H chain:

[0121] Preferably, the part of the clostridial neurotoxin H chain is a neurotoxin heavy chain of one of the following: Clostridium botulinum subtype A, Clostridium botulinum subtype B, Clostridium botulinum subtype C, Clostridium botulinum subtype D, Clostridium botulinum subtype E, Clostridium botulinum subtype F, Clostridium botulinum subtype G, Clostridium baratii and Clostridium butyricum; or the part of the clostridial neurotoxin H chain is a neurotoxin H chain of Clostridium tetani or is derived therefrom; and / or

[0122] The second domain comprises an amino acid sequence that is at least 35%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 99% or 100% identical to any one of SEQ ID NOs: 17-23.

[0123] Furthermore, the first protease is not a protease existing in the human digestive tract, that is, there is no protease in the human digestive tract that can highly specifically cut the first enzyme cleavage site, or in other words, under most normal conditions, the first enzyme cleavage site cannot be cleaved by the protease existing in the human digestive tract. In this way, the problem of poisoning caused by accidental ingestion into the digestive tract during use is avoided, thereby ensuring safe use.

[0124] The digestive tract mentioned in this article refers to the very long muscular tube that extends from the mouth to the pharynx, esophagus, stomach, small intestine, large intestine, and finally to the anal canal, including the mouth, pharynx, esophagus, stomach, small intestine (duodenum, jejunum, ileum), large intestine (cecum, appendix, colon, rectum) and anal canal.

[0125] In one example, the specific part of the human body is human skin tissue, that is, the first protease exists in the human skin tissue.

[0126] The term "skin tissue" used herein refers to the entire "skin" of the body, including the scalp and mucous membranes. The epidermis is the outermost layer of the skin, which covers the entire body and has a protective function.

[0127] The layers of skin tissue can be divided into three parts: epidermis, dermis, and subcutaneous tissue:

[0128] (I) Epidermis

[0129] The epidermis is the outermost layer of the skin, which covers the whole body and has a protective function. The epidermis has no blood vessels (so it will not bleed after being scratched), but it has many tiny nerve endings. The epidermis can be divided into 5 layers according to cell morphology, from the outside to the inside: stratum corneum, stratum lucidum, stratum granulosum, stratum spinosum, and stratum basale.

[0130] 1. Stratum corneum

[0131] The stratum corneum is the outermost layer of the epidermis, composed of 4 to 8 thin, flat layers of dead keratinized cells overlapping each other.

[0132] 2. Transparent layer

[0133] The clear layer is composed of 2-3 layers of flat, anucleated, transparent keratinized cells.

[0134] 3. Granular layer

[0135] The granular layer is composed of 2-5 layers of thick flat cell nuclei. Its characteristic is that these cells have no ability to divide and are almost dead, and transparent keratin granules can be seen in the cells. This layer has the function of refracting light and can reduce the penetration of ultraviolet rays into the body.

[0136] 4. Spinous cell layer

[0137] The spinous cell layer consists of 4-10 layers of polygonal cells with spines and is the thickest layer in the epidermis. There are gaps between the cells in this layer. There is glycosaminoglycan between the cells. This sugar is hydrophilic and is conducive to the exchange of substances with the surrounding. There are also granular phospholipids and acidic mucopolysaccharides in the cytoplasm, which is the place for lymph circulation and material exchange. It contains many sensory nerve endings, tissue fluid that senses various external stimuli, and can provide nutrition for cells.

[0138] 5. Basal layer

[0139] The basal cell layer is the innermost layer of the epidermis, connected to the dermis in a wavy manner, and is composed of 2-4 layers of cells of different shapes. This layer is the proliferative part of the epidermis. The proliferated new cells move to the outer layer and gradually differentiate into cells of other layers.

[0140] (ii) Genuine leather

[0141] The cellular components of the dermis include fibroblasts, macrophages, and mast cells [2]. Collagen fibers, elastic fibers, and matrix are all secreted by fibroblasts. Reticular fibers are immature collagen fibers and are not an independent component. The thickness of the dermis is closely related to the amount of fibrous tissue and matrix, and is closely related to the density, fullness, relaxation, and wrinkling of the skin. In recent years, it has attracted more and more attention from cosmetic skin scientists.

[0142] 1. Collagen fibers are the most abundant component in the dermal connective tissue. Under the epidermis, the collagen fibers near the epidermal appendages and blood vessels are small and have no fixed direction, while the collagen fibers in other parts of the dermis are combined into bundles. The collagen fibers are thinner as they go up in the dermis, and thicker as they go down. In the middle and lower parts of the dermis, the direction of the collagen bundles is almost parallel to the skin surface, and they are intertwined with each other, extending in various directions on a horizontal plane. Collagen fibers are considered to be the dermal components that are most closely related to skin aging.

[0143] 2. Reticular fibers can be seen as newly formed, thin collagen fibers. Reticular fibers appear first during the embryonic period. In normal adult skin, reticular fibers are rare and are only found under the epidermis, around sweat glands, sebaceous glands, hair follicles and capillaries. Reticular fibers under the epidermis are arranged in a reticular pattern. Reticular fibers are also surrounded by each fat. Reticular fibers can proliferate in large quantities in cases of wound healing or lesions with active fibroblast proliferation and new collagen formation.

[0144] 3. Elastic fibers are much thinner than collagen fibers and are wavy. Elastic fibers are thickest in the dermis. They are arranged in the same direction as collagen bundles and can be wrapped between collagen bundles, parallel to the epidermis. In the papillary bodies under the epidermis, the tiny elastic fibers rise almost vertically to the subepidermis and end below the junction of the epidermis and dermis. Elastic fibers are closely related to skin elasticity.

[0145] 4. The matrix is ​​an amorphous substance that fills the gaps between collagen fibers and collagen bundles. The matrix in normal dermis mainly contains non-sulfate acidic mucopolysaccharides, such as hyaluronic acid (also known as hyaluronic acid). Although the content of hyaluronic acid in normal skin is very small, it can absorb 1000 times more water, so it is of great significance in anti-wrinkle and anti-aging of the skin.

[0146] 5. Cells: The dermis contains fibroblasts, mast cells, histiocytes, lymphocytes and a small amount of true bark mitotic cells, melanophages, and Langerhans cells. Fibroblasts can produce collagen fibers, elastic fibers, reticular fibers and matrix. At the same time, they are the main tissue repair cells after deep skin tissue damage.

[0147] (III) Subcutaneous tissue

[0148] Subcutaneous tissue is the loose connective tissue and fat tissue below the skin, connecting the skin and muscles, often called superficial fascia. Subcutaneous tissue is between the skin and deep tissue, giving the skin a certain degree of mobility.

[0149] Subcutaneous tissue is composed of loose connective tissue and fat lobules, which are connected to the dermis above and to the fascia, muscle aponeurosis or periosteum below. The cytoplasm of fat cells is transparent, and the nucleus is biased towards the inner edge of the cell. Fat cells gather to form primary lobules, and many primary lobules form secondary lobules, which are surrounded by fibrous septa or trabeculae. The fat septa contain blood vessels, lymphatic vessels, nerves, small sweat glands and apocrine sweat glands.

[0150] In one example, the first protease is selected from any one or more of the following:

[0151] Epidermis-specific kallikreins (KLKs, human kallikrein-related peptidases) (e.g., KLK5, KLK6, KLK7), SASPase, Caspase-14, Furin protease.

[0152] Epidermis-specific kallikreins (KLKs) belong to a family of serine proteases that are expressed in the stratum granulosum. KLKS is a secreted trypsin-like serine protease that appears to be most abundantly expressed in human skin, particularly in the upper stratum spinosum and stratum granulosum, where keratinocytes undergo terminal differentiation and transform into flat, brick-like structures that form the stratum corneum, the outermost epidermal layer and a barrier to the external environment [1].

[0153] [1] Debela et al., J Mol Biol, 373, 1017-1031 (2007); and Tan et al., J Med Chem. 2015 Jan 22;58(2):598-612 (2014).

[0154] KLKs are encoded by 15 different genes, each containing 5 exons and arranged in tandem on human chromosome 19. The 15 human KLK genes are located on chromosome 19q13.4, constituting the largest continuous serine protease cluster in the human genome. These genes usually consist of five coding exons and in some cases one or two 5' non-coding exons, encoding kallikrein-related peptidases KLK1 to KLK15. All KLK genes encode single-chain preproproteins containing a chymotrypsin or trypsin-like catalytic domain of 224-237 residues [2].

[0155] [2] Debela et al., Biol Chem 389, 623-632 (2008).

[0156] Of the 15 members of the KLK family, 11 are expressed in the skin, with their range being limited to the epidermis and skin appendages. Gene expression analysis showed that KLK1 and KLK11 are the most highly expressed KLKs in the skin. KLK4, KLK5, KLK6, KLK7, and KLK13 are moderately expressed, while the mRNA of KLK8 is rarely detected under steady-state conditions [3]. In terms of expression location, the mRNAs of KLK6, KLK9, KLK10, KLK13, and KLK14 appear to be strictly restricted to the granular layer of the healthy epidermis, while the mRNAs of KLK1, KLK4, and KLK11 are present in both the spinous layer and the basal layer of keratinocytes.

[0157] Most KLK genes expressed in the epidermis are also expressed in the skin appendages [3]. At the protein level, KLKs are generally more widely distributed in the epidermis. KLK5 is present in the stratum granulosum and stratum corneum, while KLK6 is present throughout the epidermis but is only partially enriched in the stratum granulosum. KLK7 is detected in both the basal and supragranular layers of the epidermis but is barely detectable in the areas between the two.

[0158] [3]N.Komatsu,M.Takata,N.Otsuki,T.Toyama,R.Ohka,K.Takehara,K.Saijoh,Expression and localization of tissue kallikrein mRNAs in human epidermis and appendages, J. Invest. Dermatol. 121 (2003) 542–549. https: / / doi.org / 10.1046 / j.1523-1747.2003.12363.x.

[0159] In addition, KLK8 and KLK13 have been observed in the stratum corneum and stratum granulosum, as well as in the appendages of healthy skin [4, 5]. Thus, the distribution of the protein is broader than that of the gene expression, indicating the diffusion of KLKs in the epidermis. Of all the KLKs, KLK14 appears to be the most specific to the skin, with low levels in other tissues but relatively high levels in the skin, at 250 ng / g of total protein [6, 7].

[0160] [4]N.Komatsu,K.Saijoh,T.Toyama,R.Ohka,N.Otsuki,G.Hussack,K.Takehara,EPDiamandis,MultipletissuekallikreinmRNAandprotein expressioninnormalskinandskindiseases,Br.J.Dermatol.153(2005)274–281.https: / / doi.org / 10.1111 / j.1365-2133.2005.06754.x.

[0161] [5]M.Kishibe,Y.Bando,R.Terayama,K.Namikawa,H.Takahashi,Y.Hashimoto,A.Ishida-Yamamoto,Y.Jiang,B.Mitrovic,D.Perez,H.Iizuka,S.Yoshida,Kallik rein8isinvolvedinskindesquamationincooperationwithotherkallikreins,J.Biol.Chem.282(2007)5834–5841.https: / / doi.org / 10.1074 / jbc.M607998200.

[0162] [6] JLVShaw,EPDiamandis,Distributionof15humankallikreinsintissuesandbiologicalfluids,Clin.Chem.53(2007)1423–1432.https: / / doi.org / 10.1373 / clinchem.2007.088104.

[0163] [7]CA IPMichael,JLVShaw,L.Luo,MCGhosh,A.Soosaipillai,L.Grass,D.Katsaros,EPDiamandis,Expressionandfunctionalcharacterizationofthe cancerrelatedserineprotease,humantissuekallikrein14,J.Biol.Chem.282(2007)2405–2422.https: / / doi.org / 10.1074 / jbc.M608348200.

[0164] SASPase is a protease found in human skin with a molecular weight of 28 kDa. SASPase is specifically expressed in the stratum granulosum of human skin and produces a 14 kDa protein by autolysis. Recombinant SASPase has been reported to exhibit autolytic activity and degrade exogenous substrates such as insulin and casein. However, its function in the epidermis has not been determined [8].

[0165] [8] Bernard D. et al., J. Invest. Dermatol. 125, 278-287, 2005

[0166] The Caspase family belongs to cysteine ​​proteases, which are equivalent to ced-3 in nematodes and have a high degree of homology. These proteases have the following characteristics: ① They always cut off the substrate after aspartic acid, so they are named Caspase (cysteineaspartate-specific protease). ② The enzyme activity depends on the nucleophilicity of the cysteine ​​residue. ③ It usually exists in the form of zymogen, which is a heterotetramer composed of two large and two small subunits. The large and small subunits are encoded by the same gene. After activation, the precursor is cleaved to produce two active subunits. These proteases are key enzymes that cause cell apoptosis. Once the signal transduction pathway is activated, Caspase is activated, and then a cascade reaction of apoptotic proteases occurs. The enzymes in the cell are activated and can degrade important proteins in the cell, eventually leading to irreversible cell apoptosis.

[0167] Caspase-14 (CASP14) is a member of the caspase family and plays a key role in the formation and regulation of the skin stratum corneum.

[0168] Furin is an intracellular protease that proteolytically activates a large number of pre-protein substrates in secretory pathway compartments by cleaving a cluster of basic residues, usually in the form of RX(K / R)R.

[0169] In one example, the first enzyme cleavage site contains an amino acid sequence that is at least 50%, 60%, 85%, 90%, 99% or 100% identical to any one of SEQ ID NOs: 1-4, SEQ ID NO: 50 (RXXR) and SEQ ID NO: 51 (RRXX).

[0170] In SEQ ID NO:5049 and SEQ ID NO:51, "X" in RXXR and RRXX is any amino acid. Preferably, XX in RXXR is RK, TK or TR; "XX" in RRXX is SV or KR.

[0171] In one example, the single-chain polypeptide provided by the present invention is characterized in that it also includes: one or more of a signal peptide for increasing the expression amount, a quantitative protein for quantification, and a tag protein.

[0172] Furthermore, one or more of the signal peptide, quantitative protein and tag protein are defined as follows:

[0173] The signal peptide comprises an amino acid sequence that is at least 85%, 90%, 99% or 100% identical to SEQ ID NO:24;

[0174] The quantitative protein is a fluorescent protein;

[0175] The tag protein is one or more of a His tag, a GST tag, an MBP tag and a Strep-tagII tag, or contains an amino acid sequence that is at least 85%, 90%, 99% or 100% identical to SEQ ID NO:25.

[0176] "One or more of the signal peptide, quantitative protein and tag protein are respectively limited as follows", for example, only the above-mentioned limitations corresponding to the signal peptide, quantitative protein and tag protein are made, or the above-mentioned limitations corresponding to the signal peptide, quantitative protein and tag protein are made, or the above-mentioned limitations corresponding to any two of the signal peptide, quantitative protein and tag protein are made, etc.

[0177] In one example, the single-chain polypeptide also includes: two second enzyme cleavage sites located at the N-terminus of the first structure and the C-terminus of the second structure, respectively, and the second protease that cleaves the second enzyme cleavage site cannot cleave the first enzyme cleavage site. In this way, the first domain, the first enzyme cleavage site and other parts other than the second domain in the single-chain polypeptide can be cut and removed by enzymatic cleavage of the two second enzyme cleavage sites, such as removing the signal peptide, quantitative protein, label protein, etc., to obtain a single-chain polypeptide with only the first domain, the first enzyme cleavage site and the second domain remaining.

[0178] In one example, the first enzyme cleavage site and / or the second enzyme cleavage site will not usually be cleaved by the protease that is exposed during the synthesis of the single-chain polypeptide by expressing the single-chain polypeptide in the host cell in vivo or by the in vitro synthesis system involving the cell extract from the host cell. That is, when the single-chain polypeptide is obtained by expressing the single-chain polypeptide in the host cell in vivo, or when the single-chain polypeptide is synthesized by in vitro synthesis involving the host cell extract, the first enzyme cleavage site and / or the second enzyme cleavage site will not usually be cleaved by the protease that is exposed in these two ways. In this way, when the first cleavage site meets this premise, it will not be easily activated during production, thereby ensuring a certain level of production safety. When the second enzyme cleavage site meets this premise, it can maintain a certain structure of the single-chain polypeptide as needed. For example, in the process of producing the single-chain polypeptide, the product can be purified during production because it carries a tagged protein.

[0179] In one example, the second enzyme cleavage site is designed to be highly specific to the second protease, that is, as mentioned above, the second enzyme cleavage site has a unique correspondence with the second protease, so that the second enzyme cleavage site can only be cleaved by a specific second protease under most normal circumstances (that is, under normal circumstances), and will not be arbitrarily cleaved during production, so that the single-chain polypeptide can maintain a certain structure before the second enzyme cleavage site is cleaved.

[0180] Further, the second protease is not an enzyme that usually occurs, for example, not a protease in the human body, and the protease in the human body herein refers to a protease that is not usually present in the human body. In this way, it is reduced that, for example, the protease in the human body is cut during production, and the structure is changed at an inappropriate time.

[0181] In one example, preferably, the second protease is selected from non-human enterokinase, tobacco etch virus protease, a protease derived from Bacillus subtilus, a protease derived from Bacillus amyliquifaciens, a protease derived from a rhinovirus, papain, a homolog of insect papain or a homolog of crustacean papain.

[0182] In one example, the second restriction site contains an amino acid sequence that is at least 85%, 90%, 99% or 100% identical to any one of SEQ ID NOs: 5 to 9. In SEQ ID NO: 6: EXXYXQS / G, X refers to any amino acid.

[0183] In one example, when the second domain contains an amino acid sequence that is at least 80%, 85%, 90%, 95%, 99% or 100% identical to SEQ ID NO: 17, the lysine at the position corresponding to the 423rd position of the amino acid sequence of the second domain is mutated to a non-lysine. For example, lysine is mutated to asparagine, glutamic acid or alanine, thereby preventing the second domain from being cleaved by Trypsin and losing its activity.

[0184] The lysine at position 423 herein refers to the lysine at position 423 for an amino acid sequence that is completely identical to SEQ ID NO: 17 (i.e., 100% identical), and refers to the position number of the lysine at position 423 in the amino acid sequence that is not completely identical to SEQ ID NO: 17, and refers to the position number of the lysine at position 423 in the amino acid sequence at that time that is within a reasonable misalignment range with the position number of position 423 of SEQ ID NO: 17. The reasonable misalignment range here refers to the fact that for those skilled in the art, when the identity of the amino acid sequence, that is, the homology with the amino acid sequence used for comparison reaches more than 80%, the position number will have a certain misalignment towards the N-terminus or C-terminus compared with the amino acid sequence used for comparison, and this misalignment is acceptable.

[0185] For example, compared with the sequence of SEQ ID NO: 17, an amino acid sequence that has at least 80% identity with SEQ ID NO: 17 has an amino acid lysine at the position 423 that is misaligned by 5 positions compared with SEQ ID NO: 17. This error range of 5 positions is within an acceptable range, so a person skilled in the art can assume that the position number 427 of the position is the lysine at the position corresponding to the 423rd position.

[0186] In one example, the intermediate amino acid sequence region sequence further includes XTXS, wherein X is not a K amino acid, and preferably, X is a Q amino acid.

[0187] In a preferred example, the structure of the intermediate amino acid sequence region sequence from the N-terminus to the C-terminus is:

[0188] XTXS-linker (L3)-at least one first enzyme cleavage site: Similarly, when there are multiple first enzyme cleavage sites, all of the first enzyme cleavage sites have the same cleavage site or are different from each other. Preferably, multiple first enzyme cleavage sites are sequentially connected from the N-terminus to the C-terminus. Further, the number of amino acids in L3 is 0-20 or 0-10 or 0-5.

[0189] There is no particular limitation on the connection between the first domain, the middle amino acid sequence region (when the middle amino acid sequence region has only the first enzyme cleavage site), and the second domain herein, and preferably, they are connected from the N-terminus to the C-terminus.

[0190] 2. Application

[0191] The aforementioned single-chain polypeptide provided by the present invention is used in any one or more of the following: skin care, plastic surgery, body shaping, and treatment by inducing muscle relaxation and relieving muscle spasms.

[0192] Specifically, the present invention also provides a single-chain polypeptide product or medicine, which includes: the aforementioned single-chain polypeptide. Preferably, the single-chain polypeptide product is used for any one or more of the following purposes: skin care, plastic surgery, body shaping, and treatment by inducing muscle relaxation and relieving muscle spasms.

[0193] In addition, when used, the above-mentioned single-chain polypeptide products or drugs can enter from a specific part by means of, for example, smearing, spraying, external application or injection, for example, by smearing into the skin tissue. After entering, it is cleaved by a specific first protease at the first cleavage site in the specific part, and the single-chain polypeptide is converted into an activated form, thereby exerting its effect.

[0194] 3. The present invention also provides a nucleic acid, comprising: a nucleotide sequence encoding the aforementioned single-chain polypeptide.

[0195] The present invention also provides a vector comprising the above nucleic acid.

[0196] The present invention also provides a host cell, comprising the above nucleic acid and / or the above vector, wherein the host cell is from a prokaryotic cell or a eukaryotic cell, and further, the cell is selected from the group consisting of one or more combinations of Escherichia coli cells, human cells, Chinese hamster cells, ovarian cells, insect cells, wheat germ cells, rabbit reticulocytes, and yeast cells.

[0197] Furthermore, the host cell is selected from yeast cells, and further, the yeast cell is selected from: a combination of one or more of Saccharomyces cerevisiae and Kluyveromyces yeast. In another preferred embodiment, the Kluyveromyces yeast is selected from: a combination of one or more of Kluyveromyces lactis, Kluyveromyces marxianus and Kluyveromyces dobsonii.

[0198] The present invention also provides an in vitro cell-free synthesis system, comprising: synthesizing the single-chain polypeptide using an mRNA or DNA template encoding the single-chain polypeptide.

[0199] In one example, the in vitro cell-free synthesis system includes any one or more of the following:

[0200] (1) an mRNA or DNA template encoding the aforementioned single-chain polypeptide;

[0201] (2) Cell extract, wherein the cell extract is a yeast cell extract:

[0202] In one example, the cell extract is derived from the following group of strains: any one or more combinations of Saccharomyces cerevisiae, Pichia pastoris and Kluyveromyces; preferably, the strain from which the yeast cell extract is derived is Kluyveromyces, more preferably Kluyveromyces lactis;

[0203] (3) Any one or more of the following components:

[0204] Amino acid mixture, dNTP, RNA polymerase, DNA polymerase, energy supply system, polyethylene glycol and aqueous solvent.

[0205] 4. Preparation method of single-chain polypeptide:

[0206] In vitro synthesis of the single-chain polypeptide is carried out using mRNA or DNA template encoding the above-mentioned single-chain polypeptide.

[0207] Deserve.

[0208] In one example, the in vitro synthesis reaction is carried out in a reaction system including the aforementioned in vitro cell-free synthesis system. Preferably, the volume ratio of the DNA template to other components involved in the in vitro synthesis reaction is in the range of 1:10-1:50 or 1:20-1:40 or 1:25-1:35 or 1:30.

[0209] In one example, the cell-free in vitro synthesis system includes: yeast cell extract, amino acid mixture, dNTP, RNA polymerase, DNA polymerase, energy supply system, polyethylene glycol and aqueous solvent.

[0210] In one example, the yeast cell extract is from the group consisting of any one or more of Saccharomyces cerevisiae, Pichia pastoris and Kluyveromyces; preferably, the yeast cell extract is from Kluyveromyces, more preferably Kluyveromyces lactis.

[0211] In one example, yeast extract accounts for 50-80% of the volume of the entire cell-free in vitro synthesis system.

[0212] The present invention expresses and purifies the aforementioned single-chain polypeptide through the aforementioned in vitro synthesis reaction, which has a short cycle and is easy to operate. Moreover, because an in vitro preparation method using the addition of mRNA or DNA template is used, a DNA template of a plasmid-modified gene can be used, and there is no risk of leakage of toxic strains.

[0213] In one example, the method for preparing the single-chain polypeptide further includes: digesting the obtained single-chain polypeptide or the obtained and purified single-chain polypeptide with a second protease to obtain a single-chain polypeptide comprising only the first domain, the first enzyme cleavage site and the second domain.

[0214] The cell-free in vitro synthesis system in the present invention includes an in vitro translation system, an in vitro transcription and translation system (IVTT system) and the like.

[0215] In vitro protein synthesis reaction refers to the reaction of synthesizing protein in an in vitro cell-free synthesis system, including at least the translation process. Including but not limited to IVTT reaction (in vitro transcription and translation reaction). In the present invention, IVTT reaction is preferred. IVTT reaction, corresponding to IVTT system, is the process of transcribing and translating DNA into protein (Protein) in vitro. Therefore, we also refer to this type of in vitro protein synthesis system as D2P system, D-to-P system, D_to_P system, DNAto-Protein system; the corresponding in vitro protein preparation method is also called D2P method, D-to-P method, D_to_P method, DNA-to-Protein method.

[0216] In the in vitro synthesis reaction of the embodiments of the present invention, the cell-free in vitro synthesis system, template, plasmid, target protein, in vitro synthesis reaction (incubation reaction), various preparation methods, various detection methods and other technical elements can also be independently selected from the following documents. Suitable implementation methods or implementation methods include but are not limited to CN111484998A, CN106978349A, CN108535489A, CN108690139A, CN108949801A, CN108642076A, CN109022478A, CN109423496A, C N109423497A, CN109423509A, CN109837293A, CN109971783A, CN109988801A, CN109971775A, CN110093284A, CN110408635A, CN110408636A, CN110551745A, CN110551700A, CN110551785A, CN110819647A, CN110845622A, CN110938649A, CN110964736A, etc. Unless otherwise in conflict with the purpose of the present invention, these documents and their citations are cited in their entirety and for all purposes.

[0217] The following further illustrates the content of the present invention based on the source of botulinum toxin type A and in combination with various experimental examples.

[0218] Example 1 DNA template preparation

[0219] 1. Construction of target plasmid:

[0220] (1) Constructing a target plasmid containing a nucleotide sequence encoding a protein structure as shown in Formula 1:

[0221] SP-8His-F2-LC-D(KTKS-F1)-HC-F2-EGFP-8His (Formula 1, N-terminal to C-terminal connection);

[0222] In the formula, D represents the middle amino acid sequence region, KTKS is a part of the natural type A botulinum toxin cleavage site, and F1 represents the first enzyme cleavage site designed by the present invention, which respectively correspond to several different first proteases, KLK5, KLK7, SASPase, and Caspase-14;

[0223] F2 is the second enzyme cleavage site, corresponding to the second protease, and the second protease in this embodiment is TEV enzyme;

[0224] SP is a signal peptide, 8His is a tag protein; EGFP is a fluorescent protein, used for quantification;

[0225] LC is the first domain. In this embodiment, the amino acid sequence of LC is SEQ ID NO: 10; HC is the second domain. In this embodiment, the amino acid sequence of HC is SEQ ID NO: 17;

[0226] The lysine 423 of HC was mutated to asparagine.

[0227] The primers in Table 1 correspond to the nucleotide sequences encoding the above protein structures corresponding to different first proteases;

[0228] According to each primer pair in Table 1, the correct sequence was obtained by the QuickChange PCR method, and different target plasmids were obtained by transformation.

[0229]

[0230]

[0231] (2) For the protein structure of the above structural formula 1, the original natural botulinum toxin A was modified by mutating the 438th and 440th lysines into alanines starting from LC, and the corresponding modified target plasmid was constructed, that is, the middle amino acid sequence region D was QTQS-F1.

[0232] The primers in Table 2 correspond to the nucleotide sequences of the transformed protein structures encoding different first proteases after being transformed.

[0233] The correct sequence was obtained by the QuickChange PCR method and transformed into different target plasmids.

[0234]

[0235] (3) Plasmid transformation

[0236] Transformation of each target plasmid was performed as follows:

[0237] Add 1 μl of target plasmid to 20 μl of DH5α, place on ice for 30 min, heat shock at 42°C for 45 s, place on ice for 2 min, add 500 μl of culture medium, and culture at 37°C with shaking for 1 h (200 rpm). Pipette 100 μl onto LB (containing antibody) plate, culture at 37°C inverted for 12-16 h, and store in a 4°C refrigerator.

[0238] (4) Extract and amplify the transformed plasmid:

[0239] Amplification system: random primers with a final concentration of 20-30 μM, 0.05-0.15 μg / mL plasmid template, 0.5-1 mM dNTP, 2×BSA, 1×phi29 reaction buffer (components: 50 mM Tris-HCl, 10 mM MgCl2, 10 mM (NH4)2SO4, 4 mM DTT, pH 7.5);

[0240] Take 10ml amplification system as an example:

[0241] Mix 10 ml of the amplification system, a plasmid with a final concentration of 4 ng / μl, and 5 μl of 0.05-0.1 mg / mL phi29 DNA polymerase, react at 37°C and 30 rpm for 2 hours, and then identify by electrophoresis using 1% agarose gel.

[0242] Example 2, In vitro cell-free protein synthesis (IVTT)

[0243] In vitro cell-free protein synthesis system: 22 mM 4-hydroxyethylpiperazineethanesulfonic acid at a final concentration of pH 7.4, 30-150 mM potassium acetate, 1.0-5.0 mM magnesium acetate, 1.5-4 mM nucleoside triphosphate mixture (adenosine triphosphate, guanosine triphosphate, cytosine triphosphate and uridine triphosphate), 0.08-0.24 mM amino acid mixture (glycine, alanine, valine, leucine, isoleucine, phenylalanine, proline, tryptophan, serine, tyrosine, cysteine, methionine, asparagine, glutamine, threonine, aspartic acid, glutamic acid, lysine, arginine and histidine), 25 mM creatine phosphate, 1.7 mM dithiothreitol, 0.27 mg / mL creatine phosphate kinase, 0.027-0.054 mg / mL T7 RNA polymerase, 1%-4% polyethylene glycol, 0.5%-2% sucrose, and finally 50-80% volume of yeast cell extract are added.

[0244] The yeast cell extract of this example is from Kluyveromyces lactis.

[0245] More specifically, the IVTT reaction was performed using the Standard product from the protein factory of Kangma (Shanghai) Biotechnology Co., Ltd.:

[0246] The amplified product (DNA template) obtained in Example 1 was added to the cell-free in vitro protein synthesis system at a volume ratio of 1:30 to the in vitro cell-free protein system, and reacted at 100 rpm in a constant temperature box at 30±2 degrees for 3 to 6 hours.

[0247] Example 3: Purification of in vitro synthesized protein: Purification was performed according to the following steps:

[0248] (1) Determine the amount of magnetic beads: The amount of magnetic beads is 1% of the amount used in the in vitro cell-free protein synthesis system.

[0249] (2) Magnetic bead cleaning: Wash three times with water before use, vortex for 15 seconds each time, and collect the magnetic beads using a magnetic rack. The amount of water used each time should be 5-10 times the amount of magnetic beads.

[0250] (3) Binding of target protein to magnetic beads: Mix the washed magnetic beads and IVTT product in a large beaker, allow to bind at 4°C, 100 rpm for 1 hour, and collect the magnetic beads into a centrifuge tube.

[0251] (4) Washing: Wash the protein-loaded magnetic beads three times with 30 mM imidazole at 180 rpm for 10 min each time. The amount of washing solution used should be 3-5 times the volume of the magnetic beads.

[0252] (5) Elute with 280 mM imidazole eluent: the amount of eluent used is twice the amount of magnetic beads used.

[0253] (6) Centrifugal separation: Centrifuge to remove residual magnetic beads, first time for 5 minutes, 12000rpm:

[0254] Among them, (4)-(5) were eluted at pH 8.0.

[0255] Example 4 Electrophoresis of the purification results

[0256] The electrophoresis results of the modified protein with KLK5 as the first protease Figure 1 shown.

[0257] Figure 1 In the figure, "+" indicates that the corresponding action has been performed, and "-" indicates that the corresponding action is missing. The disulfide bond reducing agent can reduce the disulfide bond. After the disulfide bond between the first domain and the second domain of the activated single-chain polypeptide is reduced, it will be divided into two parts, the first domain and the second domain, which are 50kDa and 100kDa in size respectively. The disulfide bond reduction is successful, indicating that the single-chain polypeptide protein with activation is synthesized in vitro.

[0258] Depend on Figure 1 It can be seen that after the modification, that is, the 438th and 440th lysines of LC were mutated into alanines (the middle amino acid sequence region is (QTQS-F1)):

[0259] The corresponding protein can be obtained by purification at pH 8.0. Before enzyme cleavage, even with the use of a disulfide bond reducing agent, the size is greater than 150 kDa, indicating that the corresponding protein has been obtained and that activation will not occur when the first enzyme cleavage site is not cleaved;

[0260] Only the second enzyme cleavage site was cleaved, and after the disulfide bond reduction, the size obtained was close to 150 kDa, indicating that the second enzyme cleavage site was successfully cleaved, and only the first domain, the first enzyme cleavage site, and the second domain were left. When the first enzyme cleavage site was not cleaved, no activation would occur.

[0261] Both the first enzyme cleavage site and the second enzyme cleavage site were cleaved and reduced with a disulfide bond reducing agent at the same time, resulting in sizes of 100 kDa and 50 kDa. This indicates that after the first enzyme cleavage site is cleaved, it can indeed be converted into an activated form of a double-chain structure in which the first domain and the second domain are connected by a disulfide bond.

[0262] Before the modification, no electrophoretic diagram of purified protein was obtained after elution, indicating that the retained natural cleavage site was easily broken.

[0263] Example 5 Enzyme Digestion Method

[0264] For the purified protein obtained in the above examples:

[0265] TEV single enzyme digestion: The purified protein was digested with TEV enzyme in 3mM GSH, 0.3mM GSSG, 20-30℃ overnight.

[0266] Double digestion: The purified protein was digested with KLK5 enzyme at 20-30°C for at least 8 hours, and then 3mM GSH, 0.3mM GSSG were added at 20-30°C and digested with TEV enzyme overnight.

[0267] Example 6 In vitro activity detection experiment of enzyme cleavage products

[0268] In order to simply, efficiently and accurately detect the activity of the cleavage product in vitro, we use the fluorescence resonance energy transfer (FRET) method, that is, when the donor and the acceptor are very close to each other (1-10nm), the photon energy is transferred from one excited fluorophore (donor) to another fluorophore (acceptor). This experiment uses a substrate system of CFP-substrate cleavage site-YFP structure. When excited with 433nm excitation light under normal conditions, the emission light signal can be received at 527nm (yellow light). When there is an active cleavage product, because the substrate system is cut by the cleavage product, when excited with 433nm excitation light, the emission light signal will be received at 476nm (blue light). The activity of the cleavage product in cleaving the substrate can be calculated by the change in the ratio of blue light to yellow light.

[0269] (I) Activity effects of double enzyme digestion products on different substrates

[0270] 1. Experimental purpose: To test the cleavage effect of the enzyme cleavage products on CFP-SNAP25 (17aa) -YFP substrate protein and CFP-SNAP25 (66aa) -YFP substrate protein.

[0271] 2. Experimental Procedure

[0272] 2.1 Reagents

[0273] 2.1.1HEPES;

[0274] 2.1.2NaCl;

[0275] 2.1.3DTT;

[0276] 2.1.4Zn(OAc)2;

[0277] 2.1.5 Purified water;

[0278] 2.1.6CFP-SNAP25(17aa)-YFP 1.9mg / mL(55.72kDa);

[0279] 2.1.7CFP-SNAP25(66aa)-YFP 2.8mg / mL(61.22kDa);

[0280] 2.1.8 Double enzyme digestion 700ug / mL;

[0281] 2.1.9Na2CO3

[0282] 2.2 Consumables

[0283] 2.2.150ml centrifuge tube;

[0284] 2.2.2 384-well ELISA plate;

[0285] 2.2.3 200 μl pipette tip;

[0286] 2.2.4 10μl pipette tip;

[0287] 2.2.51.5ml EP tube.

[0288] 2.3 Equipment

[0289] 2.3.1 ELISA reader;

[0290] 2.3.21ml pipette;

[0291] 2.3.3 200 μl pipette;

[0292] 2.3.4 10μl pipette;

[0293] 2.3.5 pH meter;

[0294] 2.3.6 Analytical balance.

[0295] 2.4 Determination process of substrate cleavage effect

[0296] 2.4.1 Prepare the cleavage reaction buffer: first weigh 0.1835 g Zn(OAc)2 using an analytical balance, then add ultrapure water and make up to 50 ml with ultrapure water to prepare a 20 mM Zn(OAc)2 solution for later use;

[0297] 2.4.2 Use an analytical balance to weigh 0.5958 g HEPEs, 0.0146 g NaCl, and 0.0154 g DTT respectively and place them in a 50 ml centrifuge tube, add 50 ul of 20 mM Zn(OAc)2 solution, then add ultrapure water to about 45 ml and mix well.

[0298] 2.4.3 Next, adjust the pH of the solution to 7.4 with 1M Na2CO3 solution, and finally use a 50ml volumetric flask to make up the cutting buffer to obtain a cutting reaction system for use;

[0299] 2.4.4 Thaw the two substrate proteins on ice;

[0300] 2.4.5 Turn on the microplate reader and its control computer, and adjust the temperature in the microplate reader reaction chamber to 37 degrees;

[0301] 2.4.6 The final reaction system of each cleavage reaction was 50ul, and different ratios (concentration ratios) of different substrates to double enzyme cleavage products were set: 8:1; 5:1; 2.5:1.

[0302] 2.4.7 Prepare the final reaction system in a 1.5ml EP tube according to the above ratio: in the reaction system of substrate: enzyme at 8:1, the concentration of double enzyme cleavage product is 140ug / ml, and the substrate concentration is 1120ug / ml; in the reaction system of substrate: double enzyme cleavage product at 5:1, the concentration of double enzyme cleavage product is 140ug / ml, and the substrate concentration is 700ug / ml; in the reaction system of substrate: double enzyme cleavage product at 2.5:1, the concentration of double enzyme cleavage product is 140ug / ml, and the substrate concentration is 350ug / ml. The total system is 50ul. After adding the substrate and double enzyme cleavage product, add the cutting reaction buffer to make up, mix well, and set up two blank controls with only CFP-SNAP25 (17aa) -YFP substrate protein and CFP-SNAP25 (66aa) -YFP substrate protein but no double enzyme cleavage product respectively;

[0303] 2.4.8 After mixing, add the final reaction system to the 384 ELISA plate and shake the plate in the ELISA reader for 2 minutes;

[0304] 2.4.9 After vibrating and mixing, adjust to the reaction program, read once every two minutes for 3 hours, and set the reading to excitation light 433nm, receiving light 476nm, excitation light 433nm, receiving light 526nm. Both excitation light of different wavelengths need to be measured;

[0305] 2.4.10 After 3 hours of reading, take out the ELISA plate and add 3ul 0.25% Trypsin to different sample wells to terminate the reaction. After adding 0.25% Trypsin, put the ELISA plate into the ELISA reader and start reading. Read once every minute for half an hour. The reading is set to excitation light 433nm, receiving light 476nm, excitation light 433nm, receiving light 526nm. Two different wavelengths of excitation light need to be measured.

[0306] 2.5 Clearing the venue

[0307] 2.5.1 The records are complete.

[0308] 2.5.2 Waste classification and disposal: Waste will be disposed of in chemical waste storage bins.

[0309] 3. Results and Analysis

[0310] Figure 4 and Figure 5 The substrate conversion rates of different concentrations of substrates CFP-SNAP25(17aa)-YFP and CFP-SNAP25(66aa)-YFP were displayed respectively. It can be seen that within a certain time range, the substrate conversion rate is linearly related to time, so the cutting effect of the double enzyme cleavage product on the two is in line with expectations, preliminarily proving that the double enzyme cleavage product is effective in in vitro experiments;

[0311] However, the linear relationship of the substrate CFP-SNAP25(17aa)-YFP was significantly better than that of CFP-SNAP25(66aa)-YFP, which means that the substrate protein CFP-SNAP25(17aa)-YFP had a better conversion rate than the substrate protein CFP-SNAP25(66aa)-YFP;

[0312] in addition, Figure 4 and Figure 5 It shows that the ratio of substrate to double enzyme cleavage product has a good linear relationship at 8:1 and 5:1, and the ratio of substrate to double enzyme cleavage product reaches a plateau at about 2 hours at 5:1, while the time for substrate to enzyme ratio at 8:1 is too long, so the subsequent experiments will use a substrate to enzyme cleavage product concentration ratio of about 5:1.

[0313] (II) Effect of TEV single enzyme cleavage

[0314] This study mainly compares the activity of TEV single-digestion products and double-digestion products to rank

[0315] In addition to the influence of TEV enzyme.

[0316] The experimental method is the same as that of "(I) Activity effect of double enzyme cleavage products on different substrates". The difference is that only the substrate CFP-SNAP25 (17aa) -YFP was selected this time. The concentration of the substrate protein CFP-SNAP25 (17aa) -YFP in the system was 800ug / ml. The TEV single enzyme cleavage product (stock solution concentration 700ug / ml) and the double enzyme cleavage product were used for comparison experiments. The concentrations of the single enzyme cleavage product and the double enzyme cleavage product were both 140ug / ml (the concentration ratio of substrate to enzyme cleavage product was close to 5:1), and two blank controls were set up with only CFP-SNAP25 (17aa) -YFP substrate protein added but no enzyme cleavage product.

[0317] Figure 6 It shows that the conversion rate of double enzyme digestion products to substrates is within a certain time range.

[0318] It shows a linear relationship, and the TEV single enzyme cleavage product has basically no active effect on the substrate. This experiment evaluated that the TEV enzyme remaining in the single enzyme cleavage product has no activity on the substrate, and TEV enzyme cleavage does not affect the activity of the single-chain polypeptide.

[0319] 3. Effect of KLK5 enzyme

[0320] This time, the main purpose was to compare the activity effects of the double enzyme digestion products and KLK5 enzyme to eliminate the influence of KLK5 enzyme.

[0321] 1. Experimental purpose: This test is to test the effect of KLK5 enzyme

[0322] 2. Experimental Procedure

[0323] 2.1 Reagents

[0324] 2.1.1HEPES;

[0325] 2.1.2NaCl;

[0326] 2.1.3DTT;

[0327] 2.1.4Zn(OAc)2;

[0328] 2.1.5 Purified water;

[0329] 2.1.6CFP-SNAP25(17aa)-YFP 26.8mg / mL(55.72kDa);

[0330] 2.1.7 Double enzyme digestion product 671ug / mL;

[0331] 2.1.8KLK5 enzyme 530ug / mL;

[0332] 2.1.9Na2CO 3;

[0333] 2.1.10Tween80.

[0334] 2.2 Consumables

[0335] 2.2.150ml centrifuge tube;

[0336] 2.2.2 384-well ELISA plate;

[0337] 2.2.3 200 μl pipette tip;

[0338] 2.2.4 10μl pipette tip;

[0339] 2.2.51.5ml EP tube.

[0340] 2.3 Equipment

[0341] 2.3.1 ELISA reader;

[0342] 2.3.21ml pipette;

[0343] 2.3.3 200 μl pipette;

[0344] 2.3.4 10μl pipette;

[0345] 2.3.5 pH meter;

[0346] 2.3.6 Analytical balance.

[0347] 2.4 Determination process of substrate cleavage effect

[0348] 2.4.1 Prepare the cutting reaction buffer. First, weigh 0.1835 g Zn(OAc)2 using an analytical balance, then add ultrapure water and make up to 50 ml with ultrapure water to prepare a 20 mM Zn(OAc)2 solution for later use.

[0349] 2.4.2 Use an analytical balance to weigh 0.5958 g of HEPEs and 0.0146 g of NaCl respectively and put them into a 50 ml centrifuge tube, add 500 ul of 20 mM Zn(OAc)2 solution (the final concentration of Zn(OAc)2 solution is 200 uM), and then add 0.1% Tween80

[0350] (Add 50ul 100% Tween80 to 50ml system) Then add ultrapure water to about 45ml and mix well;

[0351] 2.4.3 Next, adjust the pH with 1M Na2CO3 solution to 7.4, and finally use a 50ml volumetric flask to dilute the cut reaction buffer to obtain a reaction system for use. After diluting, take 10ml of the reaction system without DTT into an empty tube, then weigh the corresponding amount of DTT powder and add it to the reaction system to prepare a 0.5mM DTT buffer system for use;

[0352] 2.4.4 Thaw the CFP-SNAP25(17aa)-YFP substrate protein on ice;

[0353] 2.4.5 Turn on the microplate reader and its control computer, and adjust the temperature in the microplate reader reaction chamber to 37 degrees;

[0354] 2.4.6 Prepare each final reaction system in a 1.5 ml EP tube: the concentration of the substrate protein CFP-SNAP25 (17aa) -YFP protein in the system is 800ug / ml, the concentration of the double enzyme digestion product is 140ug / ml, and the remaining excess volume is supplemented to 50ul with the above-configured buffer; in the KLK5 digestion group, the substrate protein concentration is 800ug / ml, no double enzyme digestion product is added, only KLK5 enzyme is added, and the KLK5 enzyme concentration is 1.4ug / ml (consistent with the remaining KLK5 enzyme concentration in the double enzyme digestion product), and set up two blank controls with only CFP-SNAP25 (17aa) -YFP substrate protein added but no double enzyme digestion product;

[0355] 2.4.7 After mixing, add the final reaction system to the 384 ELISA plate and shake the plate in the ELISA reader for 2 minutes;

[0356] 2.4.8 After vibrating and mixing, adjust to the reaction program, read once every two minutes for 3 hours. The reading is set to excitation light 433nm, receiving light 476nm, excitation light 433nm, receiving light 526nm. Two different wavelengths of excitation light need to be measured;

[0357] 2.4.9 After 3 hours of reading, take out the ELISA plate and add 3ul0.25% Trypsin to different sample wells to terminate the reaction. After adding 0.25% Trypsin, put the ELISA plate into the ELISA reader and start reading. Read once every minute for half an hour. The reading is set to excitation light 433nm, receiving light 476nm, excitation light 433nm, receiving light 526nm. Two different wavelengths of excitation light need to be measured.

[0358] 2.5 Clearing the venue

[0359] 2.5.1 The records are complete.

[0360] 2.5.2 Waste classification and disposal: Waste will be disposed of in chemical waste storage bins.

[0361] Figure 7 It shows that the conversion rate of the double-enzyme cleavage product to the substrate is linear within a certain time range, while the KLK5 enzyme has basically no active effect on the substrate. This experiment evaluated the KLK5 enzyme remaining in the single-enzyme cleavage product and found that it has no activity on the substrate.

[0362] It is proved that the single-chain polypeptide provided by the present invention can play an active role through the reduction of disulfide bonds after enzyme cleavage.

[0363] (IV) In vitro activity detection of multiple first enzyme cleavage sites

[0364] 1. Press to construct: SP-8His-F2-LC-D(F11-F12)-HC-F2-EGFP-8His:

[0365] The difference between this structure and Formula 1 is that D contains two first enzyme cleavage sites, which are as follows:

[0366] Protein No. The middle amino acid sequence region (D) FA RRSVGSGYRSRIV FB GSGRRKRGSGYRSRIV FC GSRRSVGGYRSRIV FD RRSVGGYRSRIV

[0367] The botulinum toxin obtained from the structure of this example was subjected to TEV digestion (single digestion), and double digestion (HD) of TEV and KLK5, and a negative control containing only KLK5 enzyme without botulinum toxin, were used for in vitro activity detection:

[0368] 2. Experimental Procedure

[0369] 2.1 Reagents

[0370] 2.1.1 HEPES

[0371] 2.1.2NaCl

[0372] 2.1.3DTT

[0373] 2.1.4 Zn(OAc)2

[0374] 2.1.5 Purified water

[0375] 2.1.6FP1-SNAP25(17aa)-FP226.8mg / mL(55.72kDa);

[0376] 2.1.7 Double digestion (the first and second enzyme cleavage sites of HD are both digested): 671ug / mL (Double digestion)

[0377] 2.1.8 Single enzyme digestion (TEV site only): FA: 336ug / mL; FB: 277ug / mL; FC: 110ug / mL; FD:

[0378] 427ug / mL; HD (the first enzyme cleavage site is only KLK5): 100ug / mL;

[0379] 2.1.9 KLK5 enzyme 530ug / mL; 2.1.10 Na2CO3

[0380] 2.1.11Tween80

[0381] 2.1.12BSA

[0382] 2.1.13HCl

[0383] 2.1.14PMSF

[0384] 2.2 Consumables

[0385] 2.2.150ml centrifuge tube

[0386] 2.2.2 384-well ELISA plate

[0387] 2.2.3 200 μl pipette tip

[0388] 2.2.4 10μl pipette tip

[0389] 2.2.5 1.5 ml EP tube

[0390] 2.3 Equipment

[0391] 2.3.1 Microplate reader

[0392] 2.3.2 1ml pipette

[0393] 2.3.3 200 μl pipette

[0394] 2.3.4 10 μl pipette

[0395] 2.3.5 pH meter

[0396] 2.3.6 Analytical balance

[0397] 2.4 Enzyme activity determination process of Jianmei peptide 150

[0398] 2.4.1 Prepare the enzyme digestion buffer of peptide 150. First, weigh 0.1835g Zn(OAc)2 using an analytical balance, then add ultrapure water and make up to 50ml with ultrapure water to prepare a 20mM Zn(OAc)2 solution for use.

[0399] 2.4.2 Use an analytical balance to weigh 0.5958g HEPEs, 0.0146g NaCl, and 0.0154g DTT respectively and put them into a 50ml centrifuge tube, add 50ul of 20mM Zn(OAc)2 solution, then add 0.1% Tween80 (50ul 100% Tween80 is added to 50ml system), then add ultrapure water to about 45ml and mix well. In addition, prepare other buffer systems and test buffer system 2. All other conditions remain unchanged and add Zn 2+ The concentration was increased 10 times to 200uM; the buffer system 3 was tested without Tween80, and all other conditions remained unchanged, the pH was adjusted to 5 with 1M HCL, and the buffer system 4 was tested without Tween80, and all other conditions remained unchanged with the addition of 1% BSA; the buffer system 5 was tested without Tween80, and all other conditions remained unchanged with the addition of 1% BSA and 1mM PMSF.

[0400] 2.4.3 Next, use 1M Na2CO3 solution to adjust the pH (the pH in buffer system 2 has been adjusted to 5, so there is no need to adjust the pH again, and the pH of other systems should be adjusted normally) to adjust the pH of the solution to 7.4. Finally, use a 50ml volumetric flask to make up the volume of the enzyme digestion buffer and set aside.

[0401] 2.4.4 Thaw the FP1-SNAP25 (17aa)-FP2 substrate protein on ice.

[0402] 2.4.5 Turn on the microplate reader and its control computer, and adjust the temperature in the microplate reader reaction chamber to 37 degrees.

[0403] 2.4.6 Each enzyme digestion system is 50ul. This experiment is to verify the active enzymes of 5 single enzyme digestions of peptidase and optimize the enzyme digestion system of peptidase 150.

[0404] 2.4.7 Prepare each reaction system in a 1.5 ml EP tube. The concentration of the substrate protein FP1-SNAP25 (17aa) -FP2 protein in the system is 800ug / ml, and the concentration of the fitness peptide 150 is 140ug / ml. The remaining excess volume is supplemented to 50ul with enzyme digestion buffer. In the KLK5 enzyme digestion group, the substrate protein concentration is 800ug / ml, and no fitness peptide 150 is added. Only KLK5 enzyme is added, and the KLK5 enzyme concentration is 1.4ug / ml (consistent with the KLK5 enzyme concentration in double enzyme digestion). Set up two blank controls with only FP1-SNAP25 (17aa) -FP2 substrate protein added but no fitness peptide 150.

[0405] 2.4.8 After mixing, add the reaction system to the 384 ELISA plate and shake the plate in the ELISA reader for 2 minutes.

[0406] 2.4.9 After vibrating and mixing, adjust to the reaction program and read the readings every two minutes for three hours. The readings are set to excitation light 433nm, receiving light 476nm, excitation light 433nm, receiving light 526nm. Two different wavelengths of excitation light need to be measured.

[0407] 2.4.10 After 3 hours of reading, take out the ELISA plate and add 3ul0.25% Trypsin to different sample wells to terminate the reaction. After adding 0.25% Trypsin, put the ELISA plate into the ELISA reader and start reading. Read once every minute for half an hour. The reading is set to excitation light 433nm, receiving light 476nm, excitation light 433nm, receiving light 526nm. Two different wavelengths of excitation light need to be measured.

[0408] 2.5 Clearing the venue

[0409] 2.5.1 The records are complete.

[0410] 2.5.2 Waste classification and disposal: Waste will be disposed of in chemical waste storage bins.

[0411] Figure 8 It is shown in the figure that in the enzyme cleavage system containing Tween80, the double-enzyme-cut botulinum toxin has an obvious enzymatic cleavage effect on the substrate. In the single-enzyme-cutting detection of FA, FB, FC, FD, and HD (with only one first enzyme cleavage site KLK5), the botulinum toxin has no enzymatic cleavage effect on the substrate (that is, only the TEV enzyme is cleaved, and the two middle enzyme cleavage sites are not cleaved and have no activity). KLK5 has basically no enzymatic activity in the enzyme cleavage system containing Tween80.

[0412] Example 6 proves that the single-chain polypeptide provided by the present invention, due to the presence of the first enzyme cleavage site, needs to be cleaved by a highly specific first protease before it can be highly activated.

[0413] Example 7 Experiment of product prepared after double enzyme digestion

[0414] (1) Efficacy experiment

[0415] A. Experimental procedures of the injection group

[0416] The transformed target plasmid obtained in Example 1 was used to prepare a single-chain polypeptide (eluted and purified at pH 8.0) according to the method of Examples 1-3. The protein obtained by double enzyme digestion in Example 4 was subjected to the following experiment:

[0417] Purchase female CD-1 mice about 3 weeks old (13-15g) for the experiment. First, transfer the mice to the animal room for 3 days of adaptation. After the adaptation is completed, perform the injection preparation experiment on the mice. Then dilute the stock protein to 1-0.01ng / ml with phosphate buffer to prepare it as an injection. After the injection is prepared, perform the injection experiment on the mice. Grasp the mouse with your hand, fix the left hind leg of the mouse with your fingers, find the position of the mouse gastrocnemius muscle, and inject 50μl of the injection preparation at the position of the mouse gastrocnemius muscle. Inject 3 mice as a parallel experiment. After the injection, observe the state of the mouse first. If it is normal, put the mouse back in the cage. Observe and compare the syndactyly of the left and right limbs of the mouse's hind legs every day.

[0418] B. Experimental operation of smear group

[0419] The single-chain polypeptide prepared according to Examples 1-3 and the protein obtained by double enzyme digestion according to Example 4 were mixed with oleic acid, propylene glycol, Tween 80, etc. as a smear preparation (for the configuration of the smear preparation, see Chinese patent application number 202310178312.0), and the following experiment was performed:

[0420] Female CD-1 mice about 3 weeks old (13-15g) were purchased for the experiment. First, the mice were transferred to the animal room for 3 days of adaptation. After the adaptation was completed, the mice were subjected to the smear preparation experiment. After the smear preparation was prepared, the mice were subjected to the smear experiment. First, the mice were anesthetized by intraperitoneal injection of tribromoethanol, and then the hair of the left hind leg of the mouse was cleaned with a pet shaver to expose the gastrocnemius position of the mouse. After the cleaning was completed, the preparation was applied to the mice, and 200μl was applied to each preparation (100μl was applied to the gastrocnemius position of the mouse first, and then 100μl was applied after it was dried). Three mice were selected for each group of preparations for parallel experiments. After the application was completed, the state of the mice was observed, and the mice were put back in the cage after the preparation was dried. The syndactyly of the left and right limbs of the mouse's hind legs was observed and compared every day, and the mice were smeared with the preparation according to the dose of the first application.

[0421] Reference Figure 2 , the test effects of the two groups of test products are scored: the left side of the figure is a reference to the unused product, and the right side is a reference to the changes in the used product. The scores are divided into 0, 1, 2, 3, 4 and 5, a total of 5 types. The higher the score, the better the effect.

[0422] The experimental results are as follows Figure 3 As shown, the injection concentration shown in the figure is 0.3ng / ml and the smearing histone concentration is 10μg / ml.

[0423] According to the experimental results, we can see that:

[0424] (1) The injection group showed the strongest efficacy on the third day after a single dose, and the efficacy was basically restored on the fifth day after administration;

[0425] (2) The smear group was given the drug continuously for 11 days, and the strongest effect was shown on the 5th day after the drug was given. After the drug was stopped, the duration of the drug effect was significantly longer than that of the injection group.

[0426] (2) Acute oral poisoning test - intragastric gavage test

[0427] Female CD-1 mice of about 3 weeks old (13-15 g) were purchased for the experiment. The mice were first transferred to the animal room for 3 days of adaptation. After the adaptation was completed, the mice were subjected to gavage experiments. Then, the mice were gavaged with the aforementioned injection and smear preparations.

[0428] Specifically, the mouse was grasped by hand, 300 μl of the injection or smear preparation was drawn with a 1 ml syringe, and the mouse was gavaged with a No. 8 gavage needle. Three mice were gavaged for parallel experiments. After the gavage was completed, the mouse was observed. If the mouse was in a normal state, the mouse was put back into the cage. The behavior of the mouse was observed every day, and the weight of the mouse was recorded.

[0429] Experimental results: No mice died whether they were injected or smeared, and their weight gain trend was the same as that of the control group.

[0430] Example 8 Experiment without enzyme digestion

[0431] (1) According to the method of Example 1, a target plasmid containing a nucleotide sequence encoding a protein structure of Formula 1 was constructed:

[0432] LC-D-HC (Formula 2, N-terminal to C-terminal connection);

[0433] In the formula, D represents the middle amino acid sequence region, and the first enzyme cleavage sites contained in the middle amino acid sequence region correspond to several different first proteases, KLK5, KLK7, SASPase, and Caspase-14, respectively. LC is the first domain, and in this embodiment, the amino acid sequence of LC is SEQ ID NO: 10; HC is the second domain, and in this embodiment, the amino acid sequence of HC is SEQ ID NO: 17.

[0434] The specific structure is shown in Table 3:

[0435]

[0436] The amplified products (DNA templates) obtained from the structures in Table 3 were expressed and purified according to Examples 2-3 to obtain the respective proteins.

[0437] Electrophoresis was performed, and the results of the gel run showed that there was no obvious cleavage of the various proteins obtained, proving that they were not easily activated when they were not exposed to the specific first protease in vitro.

[0438] (1) Smear test

[0439] 1. Materials and Animals

[0440] 1.1 Sample information: Each sample protein is prepared at a concentration of 10 μg / ml. All samples are kept away from light and refrigerated (2°C-8°C). 1.2 Animal strain: CD1 mice, source: Zhejiang Weitong Lihua Experimental Animal Technology Co., Ltd., 24 female mice, 18-22g, SPF grade, introduction date: 20230407, laboratory animal production license number: SCXK (Zhejiang) 2019-0001, laboratory animal quality certificate number: 20220714Abzz0619000520, laboratory animal use license number: SYXK (Shanghai) 2022-0015.

[0441] 1.3 Feed source: Shanghai Proton Biotechnology Co., Ltd., SPF grade mouse maintenance feed, production license: Shanghai Feed Certificate (2018) 04001.

[0442] 2 Methods

[0443] 2.1 Detection method: DAS (Digit Abduction Score) was used to detect the degree of denervation in mice. Figure 2 standards for scoring.

[0444] 2.2 Test method: Take out the prepared sample protein and restore it to room temperature. Randomly divide the mice into groups, anesthetize the mice with 2.5% tribromoethanol intraperitoneally, shave the skin hair where the gastrocnemius muscle is located after anesthesia, wipe with 10% ethanol, apply the test solution to the gastrocnemius muscle of CD-1 mice, 3 mice for each sample, 0.2 ml for each, apply for 7 consecutive days, observe continuously after application, record the mouse death results and syndactyly results every day, and detect the strength of the effect according to the syndactyly scoring standard.

[0445] Conclusion: The results confirmed that the proteins in Table 3, after application, can exert their effects earlier and last longer than those in Control 1 and Control 2.

[0446] (2) LD50

[0447] 1. Materials and Animals

[0448] 1.1 Sample information: FfHDS (JMT-0150), colorless transparent liquid, stored in a dark place and refrigerated (2°C-8°C).

[0449] 1.2. Animal strain: CD1 mice, source: Zhejiang Weitong Lihua Experimental Animal Technology Co., Ltd., 25 female mice, 18-22g, SPF grade, introduction date: 20230217, experimental animal production license number: SCXK (Zhejiang) 2019-0001, experimental animal quality certificate number: 20220714Abzz0619000520, experimental animal use license number: SYXK (Shanghai) 2022-0015.

[0450] 1.3 Feed source: Shanghai Proton Biotechnology Co., Ltd., SPF grade mouse maintenance feed, production license: Shanghai Feed Certificate (2018) 04001.

[0452] 2. Methods

[0453] 2.1 Detection method: Determination of the potency of botulinum toxin type A in Part IV, General Chapter 3533 of the 2020 edition of the Chinese Pharmacopoeia.

[0454] 2.2 Test method: 750ug / mL of Jianmei peptide 150 (Ff) was diluted to 6 dilutions at the same geometric intervals with 0.9% sodium chloride solution. The concentrations after dilution were 2ng / ml, 1ng / ml, 0.5ng / ml, 0.25ng / ml, 0.125ng / ml, 0.0625ng / ml, and the corresponding dosages were 38.46ng / kg, 19.23ng / kg, 9.62ng / kg, 4.81ng / kg, 2.40ng / kg, and 1.20ng / kg. Female Kunming mice (SPF grade) aged 26-30 days were injected with the diluted test solution, and a total of 6 test sample concentration gradients were injected. Except for the first concentration, 5 mice were injected, and 4 mice were injected at each dilution. Each mouse was intraperitoneally injected with 0.5ml, and marked as 1, 2, 3, 4, 5, and 6 respectively. The mice were observed for 5 consecutive days after injection, and the mortality of mice was recorded every day. The bioavailability of the test article was calculated based on the dose-response curve of the animal survival rate at 4 days.

[0455] 3. Results

[0456] Data processing was performed using Excel, and graphing software was GraphPad (see Fig. 9 ), the calculation method adopts the improved Koch method formula:

[0457] LD 50 =log -1 [X m -i(Σp-0.5)]:

[0458] Where X m: the logarithm of the maximum dose group dose; i: the logarithm of the ratio of the high dose to the low dose of two adjacent groups of doses (the difference between the logarithmic doses of two adjacent groups); p: the mortality rate of animals in each group; Σp: the sum of the mortality rates of animals in each group.

[0459] Calculation results: LD50 = 6.8 ng / kg, the potency unit is 0.136 ng / U (calculated as 20 g per mouse) (ie LD50).

[0460] The results are much lower than the potency of natural botulinum toxin. (Rossetto, O.; Montecucco, C. Tables of Toxicity of Botulinum and Tetanus Neurotoxins. Toxins 2019, 11, 686. [CrossRef] [PubMed])

[0461] Botulinum neurotoxin ("BoNT", seven immunologically distinct subtypes, AG) and tetanus neurotoxin ("TeNT") are the most toxic substances known by weight, with LD50 ranging from 0.5-2.5 ng / kg when administered by intravenous or intramuscular routes (National Institute of Occupational Safety and Health, "Registry of Toxic Effects of Chemical Substances (R-TECS)," Cincinnati, Ohio: National Institute of Occupational Safety and Health (1996)).

[0462] The toxicity of wild botulinum toxin A (natural botulinum toxin A) is nearly 20 times that of the peptide we designed.

[0463] (3)ED50

[0464] 1. Experimental purpose: ED50 determination

[0465] 2. Experimental Procedure

[0466] 2.1 Reagents and consumables

[0467] 2.1.10.9% sodium chloride solution

[0468] 2.1.2Km-JMT-0150 (FfHDs, fitness peptide 150 (Ff)) 750ug / mL;

[0469] 2.1.3 26-30 day old female SPF CD-1 mice (Zhejiang Weitong Lihua Experimental Animal Technology Co., Ltd.)

[0470] 2.1.41ml medical syringe

[0471] 2.1.5 Purified water

[0472] 2.1.650ml centrifuge tube

[0473] 2.1.71ml gun tip

[0474] 2.1.8 200μl pipette tip

[0475] 2.1.9 10μl pipette tip

[0476] 2.1.10 1.5ml EP tube

[0477] 2.1.11 Mouse feed

[0478] 2.1.12 Corncob bedding for mice

[0479] 2.1.13 Mice drinking purified water

[0480] 2.2 Equipment

[0481] 2.2.1 Clean bench

[0482] 2.2.2 1ml pipette

[0483] 2.2.3 200 μl pipette

[0484] 2.2.4 10 μl pipette

[0485] 2.3Km-JMT-0150 mouse ED50 experimental operation

[0486] 2.3.1 Preparation before the experiment

[0487] 2.3.1.1 The disposable medical syringes, CD-1 mice of appropriate age, and different concentration gradients of Km-JMT-0150 required for the experiment are prepared.

[0488] 2.3.1.2 Ultraviolet sterilization of the clean bench for 30 minutes.

[0489] 2.3.1.3 Record the information of this experiment in the Animal Experiment Record.

[0490] 2.3.2 Preparation of test samples

[0491] Preparation of different gradient concentrations of Km-JMT-0150: Km-JMT-0150 was diluted to 8 dilutions at the same geometric intervals with 0.9% sodium chloride solution. The concentrations after dilution were 1.68 ng / ml, 0.84 ng / ml, 0.42 ng / ml, 0.21

[0492] ng / ml, 0.105ng / ml, 0.0525ng / ml, 0.02625ng / ml, 0.013125ng / ml, and marked as 1, 2, 3, 4, 5, 6, 7, 8 respectively.

[0493] 2.3.3 Experimental methods

[0494] 2.3.3.1 Select 24 4-week-old female SPF CD-1 mice, weigh them, and observe their living status in preparation for gastrocnemius muscle injection.

[0495] 2.3.3.2 Catch a mouse: Grab the mouse by the tail with your right hand, lift it up, place it in a mouse cage or laboratory table and pull it backwards. When it crawls forward, grab the mouse's ears and neck skin with your left thumb and index finger, place the mouse in the palm of your left hand, straighten its hind legs, hold the mouse's tail with your ring finger, and hold the mouse's hind legs with your little finger to hold it firmly.

[0496] 2.3.3.3 After the mice were firmly grasped, 8 different gradients of diluted Jianmei 150 were injected into the gastrocnemius muscle of CD-1 mice. Three mice were injected with each gradient of Jianmei 150, and the gastrocnemius injection dose was 60 μl.

[0497] 2.3.3.4 Observe the mice for 5 consecutive days after injection, and record the syndactyly of the mice every day. And calculate the ED50 result of the test article based on the dose-response curve of the animal syndactyly rate on the day when the animal syndactyly is most severe.

[0498] 2.3.4 Notes

[0499] 2.3.4.1 When preparing and diluting different gradients of Km-JMT-0150, it is necessary to mix thoroughly and then perform multiple dilutions.

[0500] 2.3.4.2 When injecting into the gastrocnemius muscle of mice, be careful to quickly insert the syringe needle into the gastrocnemius muscle 0.3 cm at a 90° angle for injection.

[0501] 2.3.4.3 After the injection is completed, to prevent leakage, slightly rotate the needle and then slowly pull it out.

[0502] 2.4 Clearing the venue

[0503] 2.4.1 Place the injected mice back into the cage, put the discarded needles into the sharps box, and put other waste into the biohazardous waste bin.

[0504] 2.4.2 Use 75% alcohol cotton balls to wipe the clean bench surface and wipe it clean.

[0505] 3. Results and Analysis

[0506] Fig.10The ED50 response curve of the experiment was obtained by plotting the mouse finger situation (the aforementioned scoring standard) against the logarithm of the mouse gastrocnemius injection dose. The ED50 (dose with a score of 2) of Km-JMT-0150 was calculated from the response curve.

[0507] 256.9pg / kg=0.2569.ng / kg.

[0508] Through the observation of the syndactyly phenomenon in mice, it can be found that after the injection of Km-JMT-0150 into the gastrocnemius muscle, the syndactyly of mice was the most serious at 48 hours. The more serious the syndactyly of mice, the slower the recovery time. On the contrary, when the syndactyly of mice is lighter, the recovery time is faster.

[0509] Calculate the safety margin (safetymarginLD50 / ED50) of Km-JMT-0150: nearly 27.

[0510] The safety margin of wild-type BoNTA1 was 13.

[0511] It can be seen that we provide a better safety margin with much lower toxicity than wild ones.

[0512] The sequences mentioned above are summarized in Table 4.

[0513]

[0514]

[0515]

[0516]

[0517]

[0518]

[0519]

[0520]

Claims

1. A single-chain polypeptide, It is characterized in that include: The first domain, the middle amino acid sequence region, and the second domain, in, The intermediate amino acid sequence region is between the first domain and the second domain, The intermediate amino acid sequence region sequence contains at least one first enzyme cleavage site, which is designed to be highly specifically cleaved by a first protease present in a specific part of the human body. After being cleaved by the first protease at the first enzyme cleavage site, the single-chain polypeptide is converted into an activated form that can inhibit the release of information substance.

2. The single-chain polypeptide according to claim 1, characterized in that: in, The first domain has a molecular weight of about 50 kDa, the second domain has a molecular weight of about 100 kDa, and the first domain has cleavage activity.

3. The single-chain polypeptide according to claim 1 or 2, characterized in that: in, The information substance is an intercellular information substance, preferably any one of a neurotransmitter, an endocrine hormone, a local chemical mediator, and a gas signal molecule, and more preferably the information substance is acetylcholine.

4. The single-chain polypeptide according to any one of claims 1 to 3, characterized in that: in, The first domain is a non-toxic cell protease or a fragment thereof that is capable of cleaving a protein of the exocytotic fusion apparatus of a target cell; The second domain has a binding portion and a transport portion, The binding part can bind to the target cell receptor and enter the endosome of the target cell through receptor-mediated endocytosis, and the transport part can transport the first domain into the cytosol of the target cell; Preferably, the first enzyme cleavage site is between the first domain and the transport portion, and / or the binding portion is carboxyl-terminal and has a molecular weight of about 50 kD, and the transport portion is amino-terminal and has a molecular weight of about 50 kD; Another preferred embodiment is that the protein of the exocytosis fusion apparatus is the neuronal snare protein, and / or the target binding site is a receptor on the presynaptic membrane of the neuron.

5. The single-chain polypeptide according to any one of claims 1 to 4, characterized in that: in, The first domain includes at least a portion of the L chain of the Clostridium neurotoxin: Preferably, the portion of the Clostridium neurotoxin L chain is the neurotoxin L chain of one of Clostridium botulinum subtypes A, B, C, D and E or is derived therefrom, and / or the first domain contains an amino acid sequence that is at least 35%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 99% or 100% identical to SEQ ID NO: 10, or contains an amino acid sequence that is at least 35%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 99% or 100% identical to any one of 11-16 except for the naturally occurring enzyme cleavage sequence; and / or The second domain comprises at least a portion of a Clostridium neurotoxin H chain, preferably a portion of the Clostridium neurotoxin H chain is a neurotoxin heavy chain of one of the following: Clostridium botulinum subtype A, Clostridium botulinum subtype B, Clostridium botulinum subtype C, Clostridium botulinum subtype D, Clostridium botulinum subtype E, Clostridium botulinum subtype F, Clostridium botulinum subtype G, Clostridium baratii and Clostridium butyricum; or a portion of the Clostridium neurotoxin H chain is a neurotoxin H chain of Clostridium tetani or is derived therefrom, and / or The second domain comprises an amino acid sequence that is at least 35%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 99% or 100% identical to any one of SEQ ID NOs: 17-23.

6. The single-chain polypeptide according to any one of claims 1 to 7, characterized in that: in, The number of amino acids in the linker (L1) between the first domain and the middle amino acid sequence region is 0-20 or 0-10 amino acids or 0-5; and / or The number of amino acids in the linker (L2) between the intermediate amino acid sequence region and the second domain is 0-20 or 0-10 amino acids or 0-5.

7. The single-chain polypeptide according to any one of claims 1 to 6, characterized in that: in, The first protease is not a protease present in the human digestive tract, Preferably, the specific part of the human body is human skin tissue, and / or at least one of the first proteases is selected from the following: Any one or more of epidermal specific kallikrein (KLKs) proteases (e.g., KLK5, KLK6, KLK7), SASPase proteases, Caspase proteases (e.g., Caspase-14), Furin proteases, and their respective variants retaining enzymatic activity; and / or, The first enzyme cleavage site contains an amino acid sequence that is at least 50%, 60%, 85%, 90%, 99% or 100% identical to any one of SEQ ID NOs: 1-4, SEQ ID NO: 50 and SEQ ID NO:

51. In SEQ ID NO:50 and SEQ ID NO:51, "X" in RXXR and RRXX is any amino acid, preferably, XX in RXXR is RK, TK or TR; "XX" in RRXX is SV or KR.

8. The single-chain polypeptide according to any one of claims 1 to 7, It is characterized in that Also includes: Any one or more of a signal peptide for increasing the expression amount, a quantitative protein for quantification, and a tag protein, Furthermore, one or more of the signal peptide, the quantitative protein and the tag protein are defined as follows: The signal peptide comprises an amino acid sequence that is at least 80%, 85%, 90%, 99% or 100% identical to SEQ ID NO:24; The quantitative protein is a fluorescent protein; The tag protein is one or more of a His tag, a GST tag, an MBP tag and a Strep-tagII tag.

9. The single-chain polypeptide according to any one of claims 1 to 8, It is characterized in that Also includes: Two second enzyme cleavage sites are respectively located at the N-terminus of the first domain and the C-terminus of the second domain, and the second protease that cleaves the second enzyme cleavage site cannot cleave the first enzyme cleavage site.

10. The single-chain polypeptide according to any one of claims 1 to 9, characterized in that: in, The first enzyme cleavage site and / or the second enzyme cleavage site are usually not cleaved by proteases that are exposed during the expression of the single-chain polypeptide in vivo by a host cell or during the synthesis of the single-chain polypeptide by an in vitro synthesis system involving cell extracts from host cells.

11. The single-chain polypeptide according to claim 9 or 10, characterized in that: in, The second enzyme cleavage site is designed to be highly specific to the second protease, Preferably, the second protease is selected from non-human enterokinase, tobacco etch virus protease, a protease derived from Bacillus subtilus, a protease derived from Bacillus amyliquifaciens, a protease derived from rhinovirus, papain, a homologue of insect papain or a homologue of crustacean papain; and / or The second enzyme cleavage site contains an amino acid sequence that is at least 85%, 90%, 99% or 100% identical to any one of SEQ ID NOs: 5-9.

12. The single-chain polypeptide according to any one of claims 1 to 11, characterized in that: in, The intermediate amino acid sequence region sequence further comprises XTXS, wherein X is not a K amino acid, and preferably: X is a Q amino acid; and / or The structure of the intermediate amino acid sequence region sequence from N-terminus to C-terminus is: XTXS-linker (L3) - at least one first enzyme cleavage site, further, the number of amino acids in L3 is 0-20 or 0-10 or 0-5, and further, the number of the first enzyme cleavage site is 1.

13. The single-chain polypeptide according to any one of claims 1 to 12, Features: When the second domain contains an amino acid sequence that is at least 80%, 85%, 90%, 95%, 99% or 100% identical to SEQ ID NO: 17, the lysine at the position corresponding to the 423rd position of the amino acid sequence of the second domain is mutated to non-lysine.

14. The single-chain polypeptide according to any one of claims 1 to 13, characterized in that: in, The first domain, the middle amino acid sequence region and the second domain are connected from the N-terminus to the C-terminus; and / or When there are multiple first enzyme cleavage sites, the multiple first enzyme cleavage sites are connected sequentially from the N-terminus to the C-terminus, all the first enzyme cleavage sites have the same cleavage site or the first enzyme cleavage sites are different, and the number of amino acids in the linker (L4) between the multiple cleavage sites is 0-20 or 0-10 amino acids or 0-5.

15. Use of the single-chain polypeptide according to any one of claims 1 to 14: The applications include any one or more of the following: skin care, plastic surgery, body shaping, and treatment by inducing muscle relaxation and relieving muscle spasms.

16. Use of the single-chain polypeptide according to any one of claims 1 to 14 in the preparation of a product or medicine for a specific purpose: The specific uses include any one or more of the following: skin care, plastic surgery, body shaping, and treatment by inducing muscle relaxation and relieving muscle spasms.

17. A single-chain polypeptide product or drug, It is characterized in that include: The single-chain polypeptide according to any one of claims 1 to 14, Preferably, the products or drugs have applications including any one or more of the following: skin care, plastic surgery, body shaping, and treatment by inducing muscle relaxation and relieving muscle spasms; Another preferred embodiment is that the product or drug is applied to a specific part of the human body by smearing, spraying, external application or injection.

18. A nucleic acid, It is characterized in that include: A nucleotide sequence encoding the single-chain polypeptide according to any one of claims 1 to 14.

19. A carrier, It is characterized in that include: The nucleic acid of claim 18.

20. A host cell, Features: The nucleic acid according to claim 18 is integrated and / or the vector according to claim 19 is included.

21. The host cell according to claim 20, Features: The host cell is derived from a prokaryotic cell or a eukaryotic cell. Further, the cell is selected from the following group: a combination of one or more of Escherichia coli cells, human cells, Chinese hamster cells, ovarian cells, insect cells, wheat germ cells, rabbit reticulocytes and yeast cells.

22. The host cell according to claim 21, characterized in that: in, The host cell is selected from yeast cells. Further, the yeast cell is selected from: a combination of one or more of Saccharomyces cerevisiae and Kluyveromyces yeast. In another preferred embodiment, the Kluyveromyces yeast is selected from: a combination of one or more of Kluyveromyces lactis, Kluyveromyces marxianus and Kluyveromyces dobsonii.

23. An in vitro cell-free synthesis system, Features: The single-chain polypeptide is synthesized using mRNA or DNA encoding the single-chain polypeptide according to any one of claims 1 to 14 as a template.

24. The in vitro cell-free synthesis system according to claim 23, It is characterized in that Includes any one or more of the following: (1) mRNA or DNA template encoding the single-chain polypeptide; (2) a cell extract, wherein the cell extract is a yeast cell extract, and further, the cell extract is derived from any one or more combinations of Saccharomyces cerevisiae, Pichia pastoris and Kluyveromyces; preferably, the yeast cell extract is derived from Kluyveromyces, more preferably Kluyveromyces lactis; (3) Any one or more of the following components: Amino acid mixture, dNTP, RNA polymerase, DNA polymerase, energy supply system, polyethylene glycol and aqueous solvent.

25. A method for preparing the single-chain polypeptide according to any one of claims 1 to 14, Features: The single-chain polypeptide is obtained by performing an in vitro synthesis reaction using mRNA or DNA encoding the single-chain polypeptide according to any one of claims 1 to 14 as a template, Preferably, the in vitro synthesis reaction is carried out in a reaction system comprising the in vitro cell-free synthesis system according to claim 23 or 24, Furthermore, the volume ratio of the DNA template to other components involved in the in vitro synthesis reaction ranges from 1:10 to 1:50 or 1:20 to 1:40 or 1:25 to 1:35 or 1:

30.

26. The preparation method according to claim 25, characterized in that: in, The cell-free in vitro synthesis system comprises: yeast cell extract, amino acid mixture, dNTP, RNA polymerase, DNA polymerase, energy supply system, polyethylene glycol and aqueous solvent; Further: The yeast cell extract is derived from any one or more combinations of Saccharomyces cerevisiae, Pichia pastoris and Kluyveromyces; preferably, the yeast cell extract is derived from Kluyveromyces, more preferably Kluyveromyces lactis.

27. The preparation method according to claim 26, characterized in that: in, The yeast cell extract accounts for 50-80% of the volume of the entire cell-free in vitro protein synthesis system.

28. The preparation method according to any one of claims 25 to 27, It is characterized in that Also includes: The obtained single-chain polypeptide including the second enzyme cleavage site is cleaved with a second protease to obtain a single-chain polypeptide including only the first domain, the middle amino acid sequence region and the second domain.

29. A nucleic acid according to claim 18, a vector according to claim 19 , use of the host cell according to any one of claims 20 to 22 and the in vitro cell-free synthesis system according to claim 23 or 24 in the preparation of the single-chain polypeptide according to any one of claims 1 to 13.